Introduction {#Sec1}
============

The dramatically rising prevalence of multi-drug-resistant microbial infections in the past few decades has become a serious health care problem. In particular, the emergence of multi-drug resistant strains of Gram-positive bacterial pathogens, for example methicillin-resistant *Staphylococcus aureus* and *Staphylococcus epidermis* and vancomycin-resistant *Enterococcus* is a problem of ever-increasing significance. One way of overcoming this challenge is control of the use of currently marketed antibiotics; another is the development of novel antimicrobial agents. Consequently, the search for new antimicrobial agents will remain an important and challenging task for medicinal chemists \[[@CR1]\].

Acquired immune deficiency syndrome (AIDS) has become a global pandemic and has claimed more lives than any other disease. According to the 2008 UNAIDS report released by the WHO, 33 million people were diagnosed as human immunodeficiency virus (HIV)-positive in 2007 \[[@CR2]\]. Human T lymphocytes are target cells for HIV replication, and the MT-4 cell line is used for the screening of anti-HIV agents. In recent years, much attention has been devoted to the search for effective chemotherapeutic agents for inhibition of HIV with minimum side effects \[[@CR3]\].

Cancer is a disease of worldwide importance. Its incidence in the developed countries is increasing, and its mortality is ranked second in the order of causes of death. A similar tendency is observed in the developing world: gradual improvement in life expectancy is associated with elevated cancer incidence and mortality. Malignancy and its consecutive burden is therefore a global problem resulting in widespread interest in cancer therapy \[[@CR4]\].

The synthesis of novel pharmacologically active molecules with reduced toxicity is of prime interest. Recently, quantitative structure--activity relationships (QSAR) have gained importance in medicinal chemistry. QSAR are predictive tools used for preliminary evaluation of the activity of chemical compounds by use of computer-aided models. Use of QSAR has increased the probability of success in the drug-discovery process and reduced the time and cost involved \[[@CR5]\].

Hydrazones have attracted the attention of many chemists owing to their wide range of biological activity. Literature reports reveal that chemistry and biology of hydrazones have been intensively investigated during the past decade. Hydrazone derivatives have been found to have antimicrobial \[[@CR6]\], anticancer \[[@CR7]\], antimycobacterial \[[@CR8]\], antimalarial \[[@CR9]\], antioxidant \[[@CR10]\], anticonvulsant \[[@CR11]\], analgesic \[[@CR12]\], anti-inflammatory \[[@CR13]\], and antidiabetic \[[@CR14]\] activity.

Motivated by these facts, and in continuation of our research efforts in synthesis, evaluation of antimicrobial activity, and QSAR studies \[[@CR15]--[@CR18]\], we report herein the synthesis, antimicrobial, antiviral, and anticancer evaluation, and QSAR studies of *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazides.

Results and discussion {#Sec2}
======================

Chemistry {#Sec3}
---------

Synthesis of the target compounds (**1**--**48**) was performed as outlined in Scheme [1](#Sch1){ref-type="fig"}. All the compounds were high-melting-point solids (m.p. \> 300 °C). The structures of the compounds **1**--**48** were ascertained on the basis of their consistent IR, NMR, and mass spectral characteristics and results from elemental (C, H, N) analysis, all of which were in full agreement with their assigned molecular structures.Scheme 1 

Antimicrobial activity {#Sec4}
----------------------

The synthesized compounds were screened for their in-vitro antibacterial activity against *S. aureus*, *Bacillus subtilis*, and *Escherichia coli* and antifungal activity against *Candida albicans* and *Aspergillus niger* by the tube dilution method \[[@CR19]\] using norfloxacin and fluconazole as reference standards for antibacterial and antifungal activity, respectively; the results are presented in Table [1](#Tab1){ref-type="table"}.Table 1Antimicrobial activity (p*MIC*/μ[M]{.smallcaps} cm^−3^) of *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazidesComp.p*MIC*sap*MIC*bsp*MIC*ecp*MIC*cap*MIC*anp*MIC*abp*MIC*afp*MIC*am11.161.161.461.461.461.261.461.3421.201.201.501.501.501.301.501.3831.191.491.491.491.491.391.491.4341.191.191.491.491.491.291.491.3751.191.491.491.491.491.391.491.4361.251.551.551.551.551.451.551.4971.211.511.511.511.511.411.511.4581.211.211.511.511.511.311.511.3991.141.141.441.441.441.241.441.32101.181.181.481.481.481.281.481.36111.191.191.491.491.491.291.491.37121.171.171.471.471.471.271.471.35131.141.141.441.441.441.241.441.32141.181.181.481.481.481.281.481.36151.171.171.471.471.471.271.471.35161.171.171.471.471.471.271.471.35171.131.131.441.441.441.241.441.32181.181.481.481.481.481.381.481.42191.171.471.471.471.471.371.471.41201.181.481.481.481.481.381.481.42211.141.441.441.441.441.341.441.38221.181.481.481.481.481.381.481.42231.171.471.471.471.471.371.471.41241.211.511.511.511.511.411.511.45251.211.511.511.511.811.411.661.51261.171.471.471.471.771.371.621.47271.211.511.511.511.811.411.661.51281.191.491.491.491.791.391.641.49291.181.181.481.481.781.281.631.42301.191.191.491.491.791.291.641.43311.191.491.491.491.791.391.641.49321.211.211.511.511.511.311.511.39331.231.531.531.531.531.431.531.47341.181.481.481.481.481.381.481.42351.191.491.491.491.191.391.341.37361.191.491.491.491.491.391.491.43371.231.531.531.531.531.431.531.47381.191.491.491.491.491.391.491.43391.181.481.181.481.481.281.481.36401.181.481.481.481.481.381.481.42411.161.461.461.461.161.361.311.34421.201.501.501.501.501.401.501.44431.111.411.411.411.411.311.411.35441.151.451.451.451.451.351.451.39451.091.091.091.391.391.091.391.21461.051.351.351.351.051.251.201.23471.201.501.501.501.501.401.501.44481.091.391.391.391.391.291.391.33SD0.040.150.080.040.150.070.090.06Std.2.61\*2.61\*2.61\*2.64\*\*2.64\*\*------\* Norfloxacin\*\* Fluconazole

Among the synthesized compounds, *N*′-\[4-\[(2-chloro-4-nitrophenylimino)methyl\]benzylidene\]-4-chlorobenzohydrazide (**6**), *N*′-\[4-\[(2-chloro-4-nitrophenylimino)methyl\]benzylidene\]-4-aminobenzohydrazide (**33**), and *N'*-\[4-\[(2-chloro-4-nitrophenylimino)methyl\]benzylidene\]-4-hydroxybenzohydrazide (**37**) were found to be effective against *S. aureus*, having p*MIC* ~sa~ values of 1.25, 1.23, and 1.23, respectively. Against *B. subtilis*, *E. coli*, and *C. albicans*, compounds **6**, **33**, and **37** emerged as the most effective antimicrobial agents with p*MIC* values of 1.55, 1.53, and 1.53, respectively (Table [1](#Tab1){ref-type="table"}). *N*′-\[4-\[(4-Chlorophenylimino)methyl\]benzylidene\]-3-nitrobenzohydrazide (**25**) and *N*′-\[4-\[(2-chlorophenylimino)methyl\]benzylidene\]-4-nitrobenzohydrazide (**27**) were found to be effective against *A. niger* with a p*MIC* value of 1.81 (for both **25** and **27**) and proved the most effective antimicrobial agents with a p*MIC* ~am~ value of 1.51.

In general, results from minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) studies (Table [2](#Tab2){ref-type="table"}) revealed that the synthesized compounds were bacteriostatic and fungistatic in action, because their MFC and MBC values were threefold higher than their MIC values (a drug is considered to be bacteriostatic/fungistatic when its MFC and MBC values are threefold higher than its MIC value) \[[@CR20]\].Table 2Minimum bactericidal/fungicidal concentrations of *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazidesComp.Minimum bactericidal/fungicidal concentration/μ[M]{.smallcaps} cm^−3^*S. aureusB. subtilisE. coliC. albicansA. niger***1**\>0.14\>0.14\>0.14\>0.140.14**2**\>0.13\>0.13\>0.13\>0.13\>0.13**3**\>0.13\>0.13\>0.13\>0.13\>0.13**4**\>0.130.13\>0.13\>0.13\>0.13**5**\>0.13\>0.13\>0.13\>0.13\>0.13**6**\>0.11\>0.11\>0.11\>0.11\>0.11**7**\>0.12\>0.12\>0.12\>0.120.12**8**\>0.120.12\>0.12\>0.12\>0.12**9**\>0.15\>0.15\>0.150.15\>0.15**10**0.130.13\>0.13\>0.130.13**11**0.130.13\>0.13\>0.13\>0.13**12**\>0.13\>0.13\>0.130.13\>0.13**13**\>0.15\>0.15\>0.15\>0.15\>0.15**14**\>0.13\>0.13\>0.13\>0.130.07**15**0.140.14\>0.14\>0.14\>0.14**16**\>0.14\>0.14\>0.14\>0.14\>0.14**17**\>0.15\>0.15\>0.150.15\>0.15**18**\>0.13\>0.13\>0.13\>0.13\>0.13**19**\>0.14\>0.14\>0.14\>0.14\>0.14**20**0.13\>0.13\>0.13\>0.13\>0.13**21**0.15\>0.15\>0.15\>0.15\>0.14**22**0.13\>0.13\>0.13\>0.13\>0.13**23**0.13\>0.13\>0.13\>0.13\>0.13**24**\>0.12\>0.12\>0.12\>0.12\>0.12**26**\>0.13\>0.13\>0.13\>0.13\>0.13**27**\>0.12\>0.12\>0.12\>0.120.06**28**\>0.13\>0.13\>0.13\>0.13\>0.13**29**\>0.13\>0.13\>0.13\>0.13\>0.13**30**\>0.130.13\>0.13\>0.130.13**31**\>0.13\>0.13\>0.13\>0.13\>0.13**32**\>0.12\>0.12\>0.12\>0.12\>0.12**33**\>0.12\>0.12\>0.12\>0.12\>0.12**34**\>0.13\>0.13\>0.13\>0.13\>0.13**35**\>0.13\>0.13\>0.13\>0.13\>0.13**36**\>0.13\>0.13\>0.13\>0.13\>0.13**37**\>0.12\>0.12\>0.12\>0.120.12**38**\>0.13\>0.13\>0.13\>0.130.13**39**\>0.13\>0.13\>0.13\>0.13\>0.13**40**\>0.13\>0.13\>0.13\>0.13\>0.13**41**\>0.14\>0.14\>0.14\>0.14\>0.14**42**\>0.13\>0.13\>0.13\>0.13\>0.13**43**\>0.16\>0.16\>0.16\>0.16\>0.16**44**\>0.14\>0.14\>0.14\>0.14\>0.14**45**\>0.16\>0.16\>0.16\>0.16\>0.16**46**\>0.18\>0.18\>0.18\>0.18\>0.18**47**\>0.13\>0.13\>0.13\>0.13\>0.13**48**0.160.16\>0.16\>0.16\>0.16Standard0.019^a^0.019^a^0.019^a^0.040^b^0.040^ba^Norfloxacin^b^Fluconazole

Antiviral activity {#Sec5}
------------------

The antiviral assays were based on inhibition of virus-induced cytopathicity in CRFK, HEL, Vero, HeLa, and MT-4 cell cultures. The results of the antiviral evaluation are given in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. None of the synthesized hydrazide derivatives inhibited viral replication at sub-toxic concentrations.Table 3Anti-feline corona virus (FIPV) and anti-feline herpes virus activity and cytotoxicity of the synthesized hydrazide derivatives in CRFK cell culturesComp.*CC* ~50~ ^a^/μg cm^−3^*EC* ~50~ ^b^/μg cm^−3^Comp.*CC* ~50~ ^a^/μg cm^−3^*EC* ~50~ ^b^/μg cm^−3^Feline corona virusFeline herpes virusFeline corona virusFeline herpes virus**1**\>100\>100\>100**26**\>100\>100\>100**2**\>100\>100\>100**27**\>100\>100\>100**3**\>100\>100\>100**28**\>100\>100\>100**4**\>100\>100\>100**29**\>100\>100\>100**5**\>100\>100\>100**30**\>100\>100\>100**6**\>100\>100\>100**31**\>100\>100\>100**7**\>100\>100\>100**32**\>100\>100\>100**8**\>100\>100\>100**33**\>100\>100\>100**9**\>100\>100\>100**34**\>100\>100\>100**10**\>100\>100\>100**35**\>100\>100\>100**11**\>100\>100\>100**36**\>100\>100\>100**12**\>100\>100\>100**37**\>100\>100\>100**13**34.1\>20\>20**38**\>100\>100\>100**14**\>100\>100\>100**39**\>100\>100\>100**15**\>100\>100\>100**40**\>100\>100\>100**16**\>100\>100\>100**41**\>100\>100\>100**17**\>100\>100\>100**42**\>100\>100\>100**18**\>100\>100\>100**43**\>100\>100\>100**19**\>100\>100\>100**44**\>100\>100\>100**20**\>100\>100\>100**45**\>100\>100\>100**21**\>100\>100\>100**46**\>100\>100\>100**22**\>100\>100\>100**47**\>100\>100\>100**23**\>100\>100\>100**48**\>100\>100\>100**24**\>100\>100\>100HHA\>1007.61.1**25**\>100\>100\>100UDA43.71.80.8Ganciclovir (μ[M]{.smallcaps})\>100\>1000.7*CRFK cells* Crandell--Rees feline kidney cells^a^50 % Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay^b^50 % Effective concentration, or concentration resulting in 50 % inhibition of virus-induced cytopathic effect, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay Table 4Cytotoxicity and antiviral activity of the synthesized hydrazide derivatives in HEL cell culturesComp.Minimum cytotoxic concentration^a^/μg cm^−3^*EC* ~50~ ^b^/μg cm^−3^Herpes simplex virus-1 (KOS)Herpes simplex virus-2 (G)Vaccinia virusVesicular stomatitis virusHerpes simplex virus-1 TK-KOS ACV^r^**1**\>100\>100\>100\>100\>100\>100**2**100\>20\>20\>20\>20\>20**3**\>100\>100\>100\>100\>100\>100**4**\>100\>100\>100\>100\>100\>100**5**\>100\>100\>100\>100\>100\>100**6**\>100\>100\>100\>100\>100\>100**7**\>100\>100\>100\>100\>100\>100**8**\>100\>100\>100\>100\>100\>100**9**100\>20\>20\>20\>20\>20**10**100\>20\>20\>20\>20\>20**11**100\>20\>20\>20\>20\>20**12**\>100\>100\>100\>100\>100\>100**13**\>100\>100\>100\>100\>100\>100**14**\>100\>100\>100\>100\>100\>100**15**\>100\>100\>100\>100\>100\>100**16**100\>20\>20\>20\>20\>20**17**\>100\>100\>100\>100\>100\>100**18**\>100\>100\>100\>100\>100\>100**19**\>100\>100\>100\>100\>100\>100**20**\>100\>100\>100\>100\>100\>100**21**\>100\>100\>100\>100\>100\>100**22**\>100\>100\>100\>100\>100\>100**23**\>100\>100\>100\>100\>100\>100**24**\>100\>100\>100\>100\>100\>100**25**\>100\>100\>100\>100\>100\>100**26**\>100\>100\>100\>100\>100\>100**27**\>100\>100\>100\>100\>100\>100**28**\>100\>100\>100\>100\>100\>100**29**\>100\>100\>100\>100\>100\>100**30**\>100\>100\>100\>100\>100\>100**31**\>100\>100\>100\>100\>100\>100**32**\>100\>100\>100\>100\>100\>100**33**\>100\>100\>100\>100\>100\>100**34**\>100\>100\>100\>100\>100\>100**35**\>100\>100\>100\>100\>100\>100**36**\>100\>100\>100\>100\>100\>100**37**\>100\>100\>100\>100\>100\>100**38**\>100\>100\>100\>100\>100\>100**39**\>100\>100\>100\>100\>100\>100**40**\>100\>100\>100\>100\>100\>100**41**\>100\>100\>100\>100\>100\>100**42**\>100\>100\>100\>100\>100\>100**43**\>100\>100\>100\>100\>100\>100**44**\>100\>100\>100\>100\>100\>100**45**\>100\>100\>100\>100\>100\>100**46**\>100\>100\>100\>100\>100\>100**47**100\>20\>20\>20\>20\>20**48**\>100\>100\>100\>100\>100\>100Brivudin (μ[M]{.smallcaps})\>2500.039629\>250250Cidofovir (μ[M]{.smallcaps})\>2501.21.210\>2502Acyclovir (μ[M]{.smallcaps})\>2500.40.4\>250\>250183Ganciclovir (μ[M]{.smallcaps})\>1000.050.08\>100\>10020^a^Amount required to cause a microscopically detectable alteration of normal cell morphology^b^Amount required to reduce virus-induced cytopathogenicity by 50 % Table 5Cytotoxicity and antiviral activity of the synthesized hydrazide derivatives in HeLa cell culturesComp.Minimum cytotoxic concentration^a^/μg cm^−3^*EC* ~50~ ^b^/μg cm^−3^Vesicular stomatitis virusCoxsackie virus B4Respiratory syncytial virus**1**100\>20\>20\>20**2**100\>20\>20\>20**3**≥20\>20\>20\>20**4**≥20\>20\>20\>20**5**≥20\>20\>20\>20**6**≥20\>20\>20\>20**7**≥20\>20\>20\>20**8**≥20\>20\>20\>20**9**≥20\>20\>20\>20**10**≥20\>20\>20\>20**11**≥20\>20\>20\>20**12**≥20\>20\>20\>20**13**100\>20\>20\>20**14**100\>20\>20\>20**15**\>100\>100\>100\>100**16**\>100\>100\>100\>100**17**\>100\>100\>100\>100**18**≥20\>20\>20\>20**19**\>100\>100\>100\>100**20**\>100\>100\>100\>100**21**\>100\>100\>100\>100**22**\>100\>100\>100\>100**23**\>100\>100\>100\>100**24**\>100\>100\>100\>100**25**\>100\>100\>100\>100**26**\>100\>100\>100\>100**27**\>100\>100\>100\>100**28**\>100\>100\>100\>100**29**\>100\>100\>100\>100**30**\>50\>50\>50\>50**31**\>100\>100\>100\>100**33**\>100\>100\>100\>100**34**\>100\>100\>100\>100**35**\>100\>100\>100\>100**36**\>100\>100\>100\>100**37**\>100\>100\>100\>100**38**\>100\>100\>100\>100**39**\>100\>100\>100\>100**40**\>100\>100\>100\>100**41**\>100\>100\>100\>100**42**\>100\>100\>100\>100**43**\>100\>100\>100\>100**44**\>100\>100\>100\>100**45**\>100\>100\>100\>100**46**\>100\>100\>100\>100**47**\>100\>100\>100\>100**48**\>100\>100\>100\>100DS-5000\>10020344(*S*)-DHPA (μ[M]{.smallcaps})\>250\>250\>250\>250Ribavirin (μ[M]{.smallcaps})\>25042210^a^Amount required to cause a microscopically detectable alteration of normal cell morphology^b^Amount required to reduce virus-induced cytopathogenicity by 50 % Table 6Cytotoxicity and antiviral activity of the synthesized hydrazide derivatives in Vero cell culturesComp.Minimum cytotoxic concentration^a^/μg cm^−3^*EC* ~50~ ^b^/μg cm^−3^Para-influenza-3 virusReovirus-1Sindbis virusCoxsackie virus B4Punta Toro virus**1**\>100\>100\>100\>100\>100\>100**2**\>100\>100\>100\>100\>100\>100**3**\>100\>100\>100\>100\>100\>100**4**\>100\>100\>100\>100\>100\>100**5**100\>20\>20\>20\>20\>20**6**100\>20\>20\>20\>20\>20**7**\>100\>100\>100\>100\>100\>100**8**100\>20\>20\>20\>20\>20**9**≥20\>20\>20\>20\>20\>20**10**100\>20\>20\>20\>20\>20**11**100\>20\>20\>20\>20\>20**12**100\>20\>20\>20\>20\>20**13**100\>20\>20\>20\>20\>20**14**100\>20\>20\>20\>20\>20**15**\>100\>100\>100\>100\>100\>100**16**\>100\>100\>100\>100\>100\>100**17**\>100\>100\>100\>100\>100\>100**18**\>100\>100\>100\>100\>100\>100**19**\>100\>100\>100\>100\>100\>100**20**\>100\>100\>100\>100\>100\>100**21**\>100\>100\>100\>100\>100\>100**22**\>100\>100\>100\>100\>100\>100**23**\>100\>100\>100\>100\>100\>100**24**\>100\>100\>100\>100\>100\>100**25**\>100\>100\>100\>100\>100\>100**26**\>100\>100\>100\>100\>100\>100**27**\>100\>100\>100\>100\>100\>100**28**\>100\>100\>100\>100\>100\>100**29**\>100\>100\>100\>100\>100\>100**30**\>100\>100\>100\>100\>100\>100**31**\>100\>100\>100\>100\>100\>100**32**\>100\>100\>100\>100\>100\>100**33**\>100\>100\>100\>100\>100\>100**34**\>100\>100\>100\>100\>100\>100**35**\>100\>100\>100\>100\>100\>100**36**\>100\>100\>100\>100\>100\>100**37**\>100\>100\>100\>100\>100\>100**38**\>100\>100\>100\>100\>100\>100**39**100\>20\>20\>20\>20\>20**40**100\>20\>20\>20\>20\>20**41**100\>20\>20\>20\>20\>20**42**\>100\>100\>100\>100\>100\>100**43**\>100\>100\>100\>100\>100\>100**44**\>100\>100\>100\>100\>100\>100**45**\>100\>100\>100\>100\>100\>100**46**\>100\>100\>100\>100\>100\>100**47**100\>20\>20\>20\>20\>20**48**100\>20\>20\>20\>20\>20DS-5000\>100\>100\>1002096100(*S*)-DHPA (μ[M]{.smallcaps})\>250\>250\>250\>250\>250\>250Ribavirin (μ[M]{.smallcaps})\>25050\>250\>250\>25050^a^Amount required to cause a microscopically detectable alteration of normal cell morphology^b^Amount required to reduce virus-induced cytopathogenicity by 50 %

Anti-HIV activity {#Sec6}
-----------------

The anti-HIV activity and cytotoxicity were evaluated against HIV-1 strain IIIB and HIV-2 strain ROD in MT-4 cell cultures using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method \[[@CR21]\]; the results are presented in Table [7](#Tab7){ref-type="table"}. The results indicated that compound **29** (*IC* ~50~ ≥ 1 μg/cm^3^) was more potent than the standard drug nevirapine (*IC* ~50~ ≥ 4 μg/cm^3^) against the HIV-2 strain ROD; compound **39** (*IC* ~50~ ≥ 4 μg/cm^3^) was found to be equipotent.Table 7Anti-HIV potential of the synthesized compounds in MT-4 cellsComp.Avg. *IC* ~50~/μg cm^−3^Avg. *CC* ~50~/μg cm^−3^HIV-1 (IIIB)HIV-2 (ROD)**1**\>53\>5353**2**\>53\>5353**3**\>56\>5656**4**\>54\>5454**5**\>49\>4949**6**\>49\>4949**7**\>37\>3737**8**\>26\>226**9**\>47\>447**10**\>53\>5353**11**\>22\>2222**12**\>57\>5757**13**\>5\>55**14**\>10\>1010**15**\>82\>882**16**\>12\>1212**17**\>67\>6767**18**\>102\>102≥102**19**\>73\>102≥73**20**\>45\>45≥45**21**\>50\>5050**22**\>65\>6565**23**\>109\>104≥109**24**\>41\>4141**25**\>90\>90≥90**26**\>77\>7777**27**\>78\>7878**28**\>42\>42≥42**29**\>1\>11**30**\>68\>6868**31**\>58\>5858**32**\>62\>6262**33**\>15\>1515**34**\>125\>125\>125**35**\>10\>102102**36**\>12\>125\>125**37**\>86\>8686**38**\>125\>125\>125**39**\>4\>44**40**\>17\>1717**41**\>59\>5959**42**\>64\>6464**43**\>73\>7373**44**\>74\>7474**45**\>70\>7070**46**\>69\>6969**47**\>59\>5959**48**\>113\>113\>113Nevirapine0.047\>4.00\>4.00Azidothymidine, zidovudine, retrovir0.0010.0016\>25Dideoxycytidine0.290.30\>20Dideoxyinosine, didanosine2.94.6\>50

Anticancer activity {#Sec7}
-------------------

The anticancer activity of the synthesized hydrazide derivatives against human colon cancer (HCT116) and breast cancer (MCF7) cell lines was determined by use of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay \[[@CR22]\]; the results are presented in Table [8](#Tab8){ref-type="table"}.Table 8Cytotoxicity (*IC* ~50~) of the synthesized compounds against human colon cell line HCT116 and breast cancer cell line MCF7Comp.*IC* ~50~/μg cm^−3^Comp.*IC* ~50~/μg cm^−3^HCT 116MCF 7HCT 116MCF 7**1**30090**25**150300**2**300100**26**450150**3**200175**27**\>1,000210**4**350120**28**60NA**5**200175**29**50NA**6**300200**30**NA400**7**300NA**31**100NA**8**200550**32**\>1,000NA**9**60150**33**60200**10**60\>1,000**34**\>1,000NA**11**70175**35**\>1,000\>1,000**12**70300**36**NA\>1,000**13**40NA**37**NANA**14**\>1,000\>1,000**38**60\>1,000**15**11035**39**NA122**16**15025**40**NA\>1,000**17**110250**41**80125**18**200200**42**70NA**19**190200**43**700112**20**1918**44**300110**21**270200**45**80122**22**30120**46**\>1,000NA**23**60200**47**350NA**24**110100**48**30400**5-FU**60.67**5-FU**60.67Data are mean values from three replicatesNA, not able to obtain *IC* ~50~ after three independent tests

In general, the synthesized compounds had poor anticancer potential. Compounds **13**, **20**, **22**, and **48** were effective against HCT116 cancer cell lines with *IC* ~50~ values of 40, 19, 30, and 30 μg/cm^3^, respectively, and compounds **15**, **16**, and **20** were effective against MCF7 cancer cell lines with *IC* ~50~ values of 35, 25, and 18 μg/cm^3^, respectively.

The results from antimicrobial, antiviral, and anticancer evaluation revealed that the nature of the substituents has a substantial effect on the biological activity of the target hydrazones; the structure--activity relationships (SAR) discussed below were deduced.

Structure--activity relationships {#Sec8}
---------------------------------

Results of antimicrobial screening indicated that presence of electron-withdrawing 2-chloro-4-nitro substituents on the phenylimino structure of compounds **6**, **33**, and **37** increases antimicrobial activity against *S. aureus*, *B. subtilis*, *E. coli*, and *C. albicans*, whereas the presence of an electron-withdrawing nitro group on the benzoic acid structure and a chloro group on the phenylimino structure increases antifungal activity against *A. niger*. It is important to note that the incubation temperature was the same for all three bacterial species and *C. albicans* (a fungus). These similar incubation conditions may be the reason for the higher activity of compounds **6**, **33**, and **37** against *C. albicans* and the bacterial species. The effect of the electron-withdrawing group in improving antimicrobial activity is supported by the studies of Sharma et al. \[[@CR23]\].The presence of an electron-releasing group on the benzoic acid structure (**13**, **29**, and **39**) increases the anti-HIV activity of the synthesized compounds.The presence of an electron-releasing group on the benzoic acid structure (**13**, **15**, **16**, **20**, and **22**) increases the anticancer potential of the synthesized compounds. The effect of an electron-releasing group in improving the anticancer potential of benzodiazepine derivatives is similar to the observation of Kamal et al. \[[@CR24]\].The presence of an imino moiety does not improve the antimicrobial and anticancer potential of the synthesized compounds except for the propylimino moiety (**48**) which improved anticancer activity against human colon cancer cell lines (HCT 116).The presence of the naphthalene-1-ylimino moiety (**47**) in the synthesized compounds does not improve antimicrobial and anticancer potential.The aforementioned results indicate that different structural requirements are essential for a compound to be selected as antibacterial or antifungal agent. This is similar to results obtained by Sortino et al. \[[@CR25]\].

QSAR studies {#Sec9}
------------

To identify the effects of substituents on antimicrobial activity, quantitative structure--activity relationship (QSAR) studies were undertaken, using the linear free energy relationship (LFER) model described by Hansch and Fujita \[[@CR26]\]. In this study, all synthesized *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazides (**1**--**48**) were used for linear regression model generation.

The standard drugs norfloxacin and fluconazole were not used for model development because they differ in structure from the synthesized compounds. Biological activity data determined as MIC values were first transformed into p*MIC* values (i.e. −log MIC, Table [1](#Tab1){ref-type="table"}); these were used as dependent variables in the QSAR study. The different molecular descriptors (independent variables), for example the logarithm of the octanol--water partition coefficient (log *P*), molar refractivity (MR), Kier's molecular connectivity (^0^ *χ*, ^0^ *χ* ^v^, ^1^ *χ*, ^1^ *χ* ^v^, ^2^ *χ*, ^2^ *χ* ^v^) and shape (*κ* ~1~, *κα* ~1~, *κα* ~2~, *κα* ~3~) topological indices, the Randic topological index (*R*), the Balaban topological index (*J*), the Wiener topological index (*W*), total energy (*Te*), energies of highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO), dipole moment (*μ*) and electronic energy (Ele. E) \[[@CR26]--[@CR31]\] were calculated for the hydrazide derivatives. Some of the values obtained are presented in Table [9](#Tab9){ref-type="table"}.Table 9Values of selected descriptors used in QSAR studies of *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazidesComp.log *Pκ* ~1~*κ* ~2~*RWTe*LUMOHOMO*μ***1**5.7220.7311.1112.702,192.00−4,220.71−0.85−8.664.92**2**6.2421.7011.2513.112,412.00−4,580.78−0.87−8.785.88**3**6.6522.6811.4113.522,655.00−4,532.36−0.79−8.654.62**4**6.6522.6811.4113.512,676.00−4,532.43−0.80−8.564.81**5**6.6522.6811.4113.512,657.00−4,532.43−0.80−8.625.18**6**6.1924.6412.3014.423,262.00−5,411.83−1.54−9.158.02**7**5.6723.6612.1414.022,908.00−5,051.73−1.12−9.014.25**8**5.6723.6612.1414.012,968.00−5,051.81−1.23−9.036.79**9**4.9220.7311.1112.722,154.00−4,181.28−0.86−8.695.62**10**5.4321.7011.2513.132,372.00−4,541.35−0.88−8.806.48**11**4.8723.6612.1414.022,984.00−5,012.41−1.46−9.158.50**12**5.8522.6811.4113.522,615.00−4,493.00−0.79−8.645.88**13**4.4220.7311.1112.702,192.00−4,081.72−0.67−8.596.19**14**4.9421.7011.2513.102,432.00−4,441.82−0.79−8.697.65**15**5.3522.6811.4113.512,676.00−4,393.43−0.64−8.475.74**16**5.3522.6811.4113.512,657.00−4,393.43−0.64−8.526.13**17**5.6720.7311.1112.702,192.00−4,016.52−0.72−8.656.30**18**6.1921.7011.2513.112,412.00−4,376.57−0.79−8.706.88**19**6.6022.6811.4113.512,676.00−4,328.23−0.70−8.515.78**20**6.1921.7011.2513.102,412.00−4,376.60−0.84−8.767.18**21**4.9220.7311.1112.702,192.00−4,181.26−0.74−8.665.05**22**5.4321.7011.2513.112,412.00−4,541.31−0.80−8.725.74**23**5.8522.6811.4113.512,657.00−4,492.96−0.71−8.585.03**24**5.6723.6612.1414.022,914.00−5,051.70−1.46−8.914.87**25**5.6723.6612.1414.012,958.00−5,051.75−1.49−8.894.32**26**5.1522.6812.0013.612,718.00−4,691.64−1.64−8.874.26**27**5.6723.6612.1414.022,974.00−5,051.70−1.65−8.934.61**28**4.3723.6612.1414.013,028.00−4,912.84−1.37−8.9111.23**29**4.9421.7011.2513.102,452.00−4,441.83−0.81−8.657.45**30**4.3723.6612.1414.012,968.00−4,912.57−1.21−8.828.33**31**4.3723.6612.1414.022,908.00−4,912.49−1.01−8.838.99**32**4.8424.6412.3014.423,205.00−5,068.67−1.12−8.829.59**33**4.8924.6412.3014.423,262.00−5,272.84−1.45−8.9211.12**34**5.4321.7011.2513.102,432.00−4,541.35−0.85−8.776.51**35**4.8723.6612.1414.022,908.00−5,012.26−1.08−8.934.77**36**4.8723.6612.1414.013,028.00−5,012.37−1.41−9.059.29**37**5.3924.6412.3014.423,262.00−5,372.37−1.50−9.079.38**38**4.8723.6612.1414.012,968.00−5,012.35−1.19−8.967.97**39**5.4321.7011.2513.102,452.00−4,541.37−0.87−8.726.04**40**5.4321.7011.2513.112,412.00−4,541.41−0.94−8.806.61**41**4.5621.7011.2513.102,432.00−4,553.12−0.80−8.718.13**45**5.0822.6811.4113.512,695.00−4,913.13−0.92−8.728.84**42**3.9420.3111.5811.691,785.00−3,882.10−0.43−8.665.44**43**4.5121.7011.8713.202,492.00−4,237.44−0.46−8.695.92**44**2.2919.3310.7811.191,554.00−3,891.18−0.52−8.736.48**46**2.9817.369.2110.191,160.00−3,578.57−0.51−8.665.77**47**5.4223.1711.7414.693,174.00−4,621.09−0.80−8.316.22**48**3.5519.3310.7811.191,554.00−3,726.27−0.43−8.665.47

Our earlier studies \[[@CR15]--[@CR17]\] indicated that multi-target QSAR (mt-QSAR) models are more suitable than one-target QSAR (ot-QSAR) models for describing antimicrobial activity. In this study, therefore, we developed multi-target QSAR models to describe the antimicrobial activity of compounds **1**--**48**.

For ot-QSAR models one should use five different equations with different errors to predict the activity of a new compound against five microbial species. Use of ot-QSAR models, which are used almost throughout the literature, were not practical, however, when we had to predict each compound's action against more than one target. In those cases we had to develop one ot-QSAR model for each target.

However, very recently interest has increased in the development of multi-target QSAR (mt-QSAR) models. As opposed to ot-QSAR, the mt-QSAR model is a single equation that considers the nature of molecular descriptors which are common and essential for describing the antibacterial and antifungal activity \[[@CR32]--[@CR35]\].

In this study, we attempted to develop three different types of mt-QSAR model, viz. an mt-QSAR model to describe the antibacterial activity of the synthesized compounds against *S. aureus*, *B. subtilis*, and *E. coli*, an mt-QSAR model to describe the antifungal activity of the synthesized compounds against *C. albicans* and *A. niger*, and a common mt-QSAR model to describe the antimicrobial (overall antibacterial and antifungal) activity of the synthesized hydrazide derivatives against all the above mentioned microorganisms.

To develop mt-QSAR models, initially we calculated the average antibacterial, antifungal, and antimicrobial activity of the hydrazide derivatives (Table [1](#Tab1){ref-type="table"}). These average antibacterial activity values were correlated with the molecular descriptors of the synthesized compounds (Table [10](#Tab10){ref-type="table"}).Table 10Correlation matrix for the antibacterial activity of *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazidesp*MIC* ~ab~log *Pκ* ~2~*RWTe*LUMOHOMO*μ*p*MIC* ~ab~1.0000.4530.5720.6360.651−0.664−0.546−0.3790.159log *P*1.0000.2580.5300.468−0.342−0.2070.046−0.264*κ* ~2~1.0000.8740.891−0.862−0.746−0.5960.332*R*1.0000.989−0.892−0.697−0.3900.319*W*1.000−0.924−0.743−0.4550.384*Te*1.0000.8620.703−0.421LUMO1.0000.791−0.320HOMO1.000−0.373*μ*1.000

A high interrelationship was observed among topological indices, the Wiener index (*W*), and the Randic index (*R*, *r* = 0.989), and a low interrelationship was observed between the lipophilic parameter log *P* and the electronic property energy of the highest occupied molecular orbital (HOMO) (*r* = 0.046). Correlation of average antibacterial, antifungal, and antimicrobial activity values with different molecular descriptors is shown in Table [11](#Tab11){ref-type="table"}.Table 11Correlation of different molecular descriptors with the antimicrobial activity of substituted hydrazide derivativesp*MIC* ~ab~p*MIC* ~af~p*MIC* ~am~log *P*0.4530.3220.473MR0.5530.6170.698^0^ *χ*0.6440.6390.770^0^ *χ* ^v^0.5820.5830.699^1^ *χ*0.6360.6480.770^1^ *χ* ^v^0.5730.5850.693^2^ *χ*0.6370.6270.759^2^ *χ* ^v^0.5310.5160.628^3^ *χ*0.5900.5290.675^3^ *χ* ^v^0.4010.3540.456*κ* ~1~0.6410.6450.771*κ* ~2~0.5720.6670.737*κ* ~3~0.4070.5620.572*κα* ~1~0.6500.6430.776*κα* ~2~0.5660.6520.725*κα* ~3~0.3400.4780.482*R*0.6360.6480.770*J*−0.409−0.473−0.525*W*0.6510.6470.778*Te*−0.664−0.603−0.763Ele. E−0.643−0.612−0.755Nu. E0.6330.6070.745I.P.0.3790.3170.421LUMO−0.546−0.629−0.700HOMO−0.379−0.317−0.421*μ*0.1590.2190.223

From the correlation matrix (Table [10](#Tab10){ref-type="table"}), it was observed that the electronic property total energy (*Te*) dominated description of the antibacterial activity of the synthesized compounds (Eq. [1](#Equ1){ref-type=""}).

LR-mt-QSAR model for antibacterial activity:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ \begin{aligned} & {\text{p}}MIC_{\text{ab}} = - 0.00011Te + 0.830 \\ & n = 48\quad r = 0.664\quad q^{2} = 0.385\quad s = 0.0533\quad F = 36.21 \\ \end{aligned} $$\end{document}$$where *n* is the number of data points, *r* is the correlation coefficient, *q* ^2^ is the cross validated *r* ^2^ obtained by the leave-one-out (LOO) method, *s* is the standard error of the estimate, and *F* is the Fischer statistic.

Because the coefficient of *Te* in Eq. ([1](#Equ1){ref-type=""}) is negative, antibacterial activity of synthesized compounds will decrease with increasing *Te* value. This is evidenced by the high antibacterial activity of compound **6** (p*MIC* ~ab~ = 1.45 μ[M]{.smallcaps}/cm^3^) which has a low *Te* value (*Te* = −5,411.83).

To improve the value of the correlation coefficient (*r*), the electronic property total energy (*Te*) was coupled with the lipophilicity log *P*; as a result the *r* value increased from 0.664 to 0.706 (Eq. [2](#Equ2){ref-type=""}).

MLR-mt-QSAR model for antibacterial activity:$$\documentclass[12pt]{minimal}
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The developed model was cross validated by the LOO method \[[@CR36]\]. The *q* ^2^ value is \<0.5 (Eq. [2](#Equ2){ref-type=""}), which showed that the developed model is invalid. According to the recommendations of Kim et al. \[[@CR37]\], however, regression models are acceptable if the value of the standard deviation (SD, Table [1](#Tab1){ref-type="table"}) is \<0.3. Because the value of standard deviation is \<0.3, the developed model (Eq. [2](#Equ2){ref-type=""}) is a valid one. Furthermore, the observed and predicted antibacterial activity values are close to each other (Table [12](#Tab12){ref-type="table"}), so the mt-QSAR model for antibacterial activity (Eq. [2](#Equ2){ref-type=""}) is a valid one. The plot of predicted p*MIC* ~ab~ against observed p*MIC* ~ab~ (Fig. [1](#Fig1){ref-type="fig"}) also favours the developed model expressed by Eq. ([2](#Equ2){ref-type=""}). Further, the plot of observed p*MIC* ~ab~ versus residual p*MIC* ~ab~ (Fig. [2](#Fig2){ref-type="fig"}) indicated that there was no systemic error in model development because the propagation of error was observed on both sides of zero \[[@CR38]\].Table 12Comparison of observed and predicted antimicrobial activity obtained by mt-QSAR modelsComp.p*MIC* ~ab~/μ[M]{.smallcaps} cm^−3^p*MIC* ~af~/μ[M]{.smallcaps} cm^−3^p*MIC* ~am~/μ[M]{.smallcaps} cm^−3^Obs.Pre.Res.Obs.Pre.Res.Obs.Pre.Res.**1**1.261.31−0.051.461.450.011.341.36−0.02**2**1.301.36−0.061.501.460.041.381.380.00**3**1.391.360.031.491.470.021.431.390.04**4**1.291.36−0.071.491.470.021.371.40−0.03**5**1.391.360.031.491.470.021.431.390.04**6**1.451.440.011.551.58−0.031.491.480.01**7**1.411.390.021.511.54−0.031.451.430.02**8**1.311.39−0.081.511.55−0.041.391.44−0.05**9**1.241.29−0.051.441.45−0.011.321.36−0.04**10**1.281.34−0.061.481.460.021.361.38−0.02**11**1.291.37−0.081.491.57−0.081.371.46−0.09**12**1.271.34−0.071.471.470.001.351.39−0.04**13**1.241.27−0.031.441.440.001.321.35−0.03**14**1.281.32−0.041.481.460.021.361.38−0.02**15**1.271.32−0.051.471.460.011.351.39−0.04**16**1.271.32−0.051.471.450.021.351.39−0.04**17**1.241.29−0.051.441.440.001.321.35−0.03**18**1.381.340.041.481.460.021.421.370.05**19**1.371.340.031.471.460.011.411.390.02**20**1.381.340.041.481.460.021.421.380.04**21**1.341.290.051.441.440.001.381.350.03**22**1.381.340.041.481.460.021.421.370.05**23**1.371.340.031.471.460.011.411.390.02**24**1.411.390.021.511.57−0.061.451.450.00**25**1.411.390.021.661.570.091.511.450.06**26**1.371.350.021.621.570.051.471.440.03**27**1.411.390.021.661.580.081.511.460.05**28**1.391.350.041.641.560.081.491.450.04**29**1.281.32−0.041.631.460.171.421.380.04**30**1.291.35−0.061.641.550.091.431.44−0.01**31**1.391.350.041.641.530.111.491.430.06**32**1.311.37−0.061.511.55−0.041.391.46−0.07**33**1.431.400.031.531.58−0.051.471.48−0.01**34**1.381.340.041.481.460.021.421.380.04**35**1.391.370.021.341.54−0.201.371.43−0.06**36**1.391.370.021.491.56−0.071.431.46−0.03**37**1.431.420.011.531.58−0.051.471.48−0.01**38**1.391.370.021.491.55−0.061.431.44−0.01**39**1.281.34−0.061.481.460.021.361.38−0.02**40**1.381.340.041.481.470.011.421.380.04**41**1.361.320.041.311.46−0.151.341.38−0.04**45**1.401.360.041.501.480.021.441.400.04**42**1.311.240.071.411.45−0.041.351.310.04**43**1.351.290.061.451.47−0.021.391.360.03**44**1.091.21−0.121.391.40−0.011.211.29−0.08**46**1.251.190.061.201.30−0.101.231.26−0.03**47**1.401.340.061.501.490.011.441.440.00**48**1.291.220.071.391.40−0.011.331.290.04 Fig. 1Plot of predicted p*MIC* ~ab~ values against observed p*MIC* ~ab~ values for linear regression model expressed by Eq. ([2](#Equ2){ref-type=""}) Fig. 2Plot of residual p*MIC* ~ab~ values against observed p*MIC* ~ab~ values for linear regression model expressed by Eq. ([2](#Equ2){ref-type=""})

Kier's second-order shape index (*κ* ~2~) was found to be the most dominating descriptor explaining the antifungal activity of the synthesized substituted hydrazide derivatives (Table [11](#Tab11){ref-type="table"}).
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It is clearly evident from Eq. ([3](#Equ3){ref-type=""}) that the antifungal activity of the synthesized compounds is positively correlated to Kier's second-order shape index (*κ* ~2~), i.e. the antifungal activity of the compounds will increase with increasing *κ* ~2~ value. High antifungal activity of compounds **25** and **27** (p*MIC* ~af~ = 1.66) having a high *κ* ~2~ value (*κ* ~2~ = 12.14) illustrates the positive correlation. Very useful topological indices of the second generation are the *κ* indices of molecular shape and flexibility \[[@CR39]\]. According to Kier, the shape of a molecule may be partitioned into attributes, each described by the count of bonds of various path lengths. The basis for devising a relative index of shape is given by the relationship between the number of paths of length *l* in the molecule *i*, ^*l*^ *P* ~*i*~, and reference values based on molecules with a given number of atoms, *n*, in which the values of ^*l*^ *P* are maximum and minimum, ^*l*^ *P* ~max~ and ^*l*^ *P* ~min~. The first-order shape attribute, *κ* ~1~, is given by the expression:$$\documentclass[12pt]{minimal}
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The second and third-order kappa indices are defined as follows:$$\documentclass[12pt]{minimal}
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Coupling of the topological index Kier's second order shape index (*κ* ~2~) with the electronic property energy of the lowest unoccupied molecular orbital (LUMO) resulted in an increase in the *r* value from 0.667 to 0.695 (Eq. [4](#Equ4){ref-type=""}).

MLR-mt-QSAR model for antifungal activity:$$\documentclass[12pt]{minimal}
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Although the *q* ^2^ value derived for Eq. ([4](#Equ4){ref-type=""}) by the LOO method was \<0.5, which made the model invalid, the low residual values observed for antifungal activity predictions using Eq. ([4](#Equ4){ref-type=""}) (Table [12](#Tab12){ref-type="table"}) and low standard deviation (Table [1](#Tab1){ref-type="table"}) resulted in the QSAR model for antifungal activity being a valid one.

The antimicrobial activity of the synthesized hydrazide derivatives was best explained by a topological index, the Wiener index (*W*) (Table [11](#Tab11){ref-type="table"}).

LR-mt-QSAR model for antimicrobial activity:$$\documentclass[12pt]{minimal}
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The Wiener index *W* = *W*(*G*) of *G* is defined as the half sum of the elements of the distance matrix:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ W = W(G) = 1/2\sum (D)ij\quad i = 1,\quad j = 1 $$\end{document}$$where (*D*)*ij* is the *ij*th element of the distance matrix which denotes the shortest graph-theoretical distance between sites *i* and *j* of *G* \[[@CR31]\].

Similar to the antifungal activity, the antimicrobial activity of the synthesized compounds also positively correlated with the Wiener index (*W*) (Table [11](#Tab11){ref-type="table"}). Addition of the electronic property energy of the lowest unoccupied molecular orbital (LUMO) to the topological index *W* resulted in the best model for describing antimicrobial activity of the synthesized compounds (Eq. [6](#Equ6){ref-type=""}).

MLR-mt-QSAR model for antimicrobial activity:$$\documentclass[12pt]{minimal}
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The electronic property LUMO, which denotes the energy of the lowest unoccupied molecular orbital, is directly related to electron affinity and characterizes the sensitivity of the molecule to attack by a nucleophile. The contribution of LUMO to describing antimicrobial activity may be attributed to the interaction of hydrazide derivatives with a nucleophilic amino acid residue, for example cysteine, of microorganisms \[[@CR40]\].

The validity and predictability of the QSAR model for antimicrobial activity, i.e. Eq. ([6](#Equ6){ref-type=""}) is evidenced by the high *q* ^2^ value (*q* ^2^ \> 0.5) obtained by the LOO method and the low residual activity values (Table [12](#Tab12){ref-type="table"}). In summary, QSAR analysis indicated the importance of the topological index, the Wiener index (*W*), and the electronic property, the energy of the lowest unoccupied molecular orbital (LUMO), in describing the antimicrobial activity of *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazides.

Generally, for QSAR studies, the biological activity of the compounds should span two to three orders of magnitude but in this study the range of antimicrobial activity of the synthesized compounds is within one order of magnitude. This is similar to results obtained by Bajaj et al. \[[@CR41]\] who stated that the reliability of the QSAR model lies in its predictive ability even though the activity data are in a narrow range. When biological activity data is in a narrow range, a low standard deviation of the biological activity justifies its use in QSAR studies \[[@CR42]\]. The low standard deviation observed in the antimicrobial activity data in Table [1](#Tab1){ref-type="table"} justifies its use in QSAR studies.

Conclusion {#Sec10}
==========

*N*′-\[4-\[(Substituted imino)methyl\]benzylidene\]-substituted benzohydrazides were synthesized and evaluated for their antimicrobial, antiviral, and anticancer potential. Antimicrobial activity results revealed that *N*′-\[4-\[(4-chlorophenylimino)methyl\]benzylidene\]-3-nitrobenzohydrazide (**25**) and *N*′-\[4-\[(2-chlorophenylimino)methyl\]benzylidene\]-4-nitrobenzohydrazide (**27**) (p*MIC* ~am~ = 1.51) were the most potent antimicrobial agents. In general, the synthesized compounds were bacteriostatic and fungistatic in action, because their MFC and MBC values were threefold higher than their MIC values. None of the synthesized compounds inhibited viral replication at sub-toxic concentrations. The results of anti-HIV screening against HIV-2 strain ROD indicated that compound **29** (*IC* ~50~ ≥ 1 μg/cm^3^) was more potent than the standard drug nevirapine (*IC* ~50~ ≥ 4 μg/cm^3^) and that **39** (*IC* ~50~ ≥ 4 μg/cm^3^) was equipotent. Compound **20** was found to be the most effective anticancer agent against both HCT116 and MCF7 cancer cell lines, with *IC* ~50~ values of 19 and 18 μg/cm^3^, respectively. QSAR analysis indicated the importance of a topological index, the Wiener index (*W*), and an electronic property, the energy of the lowest unoccupied molecular orbital (LUMO), in describing the antimicrobial activity of the synthesized compounds.

Experimental {#Sec11}
============

Starting materials were obtained from commercial sources and were used without further purification. Reaction progress was observed by thin-layer chromatography on commercial silica gel plates (Merck silica gel F~254~ on aluminum sheets) with chloroform--acetone 9:1 as mobile phase. Melting points were determined in open capillary tubes on a Sonar melting point apparatus. Nuclear magnetic resonance (^1^H and ^13^C NMR) spectra were determined using a Bruker Avance II 400 NMR spectrometer and are expressed in parts per million (*δ*, ppm) downfield from the internal standard, TMS. Compounds were dissolved in appropriate deuterated solvents. NMR data are provided with multiplicity (s, singlet; d, doublet; t, triplet; m, multiplet) and number of protons. Infrared (IR) spectra were recorded on a Varian Resolutions Pro FTIR spectrometer. Elemental analysis was performed on a Perkin--Elmer 2400 C, H, N analyzer. Mass spectra were taken on a Waters Micromass Q-ToF Micro instrument.

General procedure for synthesis of *N*′-\[4-\[(substituted imino)methyl\]benzylidene\]-substituted benzohydrazides **1**--**48** {#Sec12}
--------------------------------------------------------------------------------------------------------------------------------

A mixture of 80 mmol substituted benzoic acid and 34.04 g (43.14 cm^3^, 0.74 mol) ethanol was heated under reflux in the presence of sulfuric acid until completion of the reaction. When the reaction was complete, the reaction mixture was added to 200 cm^3^ ice-cold water and the ester formed was extracted with 50 cm^3^ ether. The ether layer was separated and, on evaporation, yielded the crude ester which was then recrystallized from alcohol. Hydrazine hydrate (99 %, 0.015 mol) was added to an ethanolic solution of ester (0.01 mol) and the mixture was heated under reflux for 5 h. The reaction mixture was then cooled and the precipitate was isolated by filtration, washed with water, dried, and recrystallized from ethanol.

A solution of 6.70 g terephthaldehyde (50 mmol) in 50 cm^3^ ethanol was added to a solution of the substituted benzoic acid hydrazide (synthesized above; 0.05 mol) in 50 cm^3^ ethanol. The mixture was heated under reflux for 5 h. The reaction mixture was then left to cool at room temperature and the precipitated hydrazone was isolated by filtration, dried, and recrystallized from ethanol.

A solution of 50 mmol of the above synthesized hydrazone in 50 cm^3^ DMF was added to a solution of 50 mmol substituted anilines/amines/naphthalen-1-amine in 50 cm^3^ DMF. The mixture was heated under reflux for 5 h followed by cooling in an ice bath and the resulting product was isolated by filtration and purified.

### *N*′-*\[4*-*\[(Phenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**1**, C~21~H~16~ClN~3~O) {#d29e14829}

Yield: 64.1 %; TLC: *R* ~f~ = 0.57; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,649 (C=O str., secondary amide), 1,506 (C=C skeletal str., phenyl nucleus), 820 (C--H out of plane bending, 1,4-disubstituted benzene ring), 730 (C--Cl str., ArCl), 706 (C--H out of plane bending, monosubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.32 (s, 1H, --CH=N), 7.92 (d, 2H, 4-chlorophenyl), 7.58 (d, 2H, benzylidene), 7.46 (m, 4H, 4-chlorophenyl, benzylidene), 7.29 (m, 5H, phenylimino) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 160.2, 153.5, 153.1, 143.1, 137.5, 136.0, 132.1, 130.4, 130.2, 129.5, 129.3, 128.5, 127.6, 127.6, 123.4, 122.5 ppm; MS (ES+, ToF): *m*/*z* = 363 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**2**, C~21~H~15~Cl~2~N~3~O) {#d29e14913}

Yield: 61.2 %; TLC: *R* ~f~ = 0.75; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,649 (C=O str., secondary amide), 1,506 (C=C skeletal str., phenyl nucleus), 815 (C--H out of plane bending, 1,4-disubstituted benzene ring), 754 (C--H out of plane bending, 1,2-disubstituted benzene ring), 730 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.42 (s, 1H, --CH=N), 7.93 (m, 4H, 4-chlorophenyl, benzylidene), 7.93 (d, 2H, benzylidene), 7.59 (d, 2H, 4-chlorophenyl), 7.35 (m, 4H, 2-chlorophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.0, 160.5, 143.4, 143.3, 137.4, 136.2, 132.4, 129.6, 129.1 ppm; MS (ES+, ToF): *m*/*z* = 397 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,3*-*Dimethylphenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**3**, C~23~H~20~ClN~3~O) {#d29e15003}

Yield: 65.5 %; TLC: *R* ~f~ = 0.79; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,650 (C=O str., secondary amide), 1,506 (C=C skeletal str., phenyl nucleus), 819 (C--H out of plane bending, 1,4-disubstituted benzene ring), 730 (C--C out of plane bending, 1,2,3-trisubstituted benzene ring), 707 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.12 (s, 1H, --CH=N), 7.96 (m, 4H, 4-chlorophenyl, benzylidene), 7.83 (d, 2H, benzylidene), 7.44 (d, 2H, 4-chlorophenyl), 7.02 (m, 3H, 2,3-dimethylphenyl), 2.40 (s, 6H, Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.6, 160.5, 151.3, 143.0, 137.3, 136.4, 132.4, 129.2, 129.0, 128.8, 127.7, 119.0, 17.6, 9.2 ppm; MS (ES+, ToF): *m*/*z* = 391 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,4*-*Dimethylphenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**4**, C~23~H~20~ClN~3~O) {#d29e15096}

Yield: 68.3 %; TLC: *R* ~f~ = 0.52; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,650 (C=O str., secondary amide), 1,506 (C=C skeletal str., phenyl nucleus), 839 (C--H out of plane bending, 1,2,4-trisubstituted benzene ring), 818 (C--H out of plane bending, 1,4-disubstituted benzene ring), 730 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.57 (s, 1H, --CH=N), 7.94 (m, 4H, 4-chlorophenyl, benzylidene), 7.81 (d, 2H, benzylidene), 7.47 (d, 2H, 4-chlorophenyl), 7.01 (s, 1H, phenylimino), 7.00 (d, 2H, phenylimino), 2.36 (s, 6H, Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.5, 160.1, 148.5, 143.1, 137.2, 136.9, 136.3, 132.7, 132.4, 130.7, 129.4, 129.3, 127.1, 122.3 ppm; MS (ES+, ToF): *m*/*z* = 391 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,5*-*Dimethylphenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**5**, C~23~H~20~ClN~3~O) {#d29e15189}

Yield: 75.3 %; TLC: *R* ~f~ = 0.55; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,649 (C=O str., secondary amide), 1,506 (C=C skeletal str., phenyl nucleus), 815 (C--H out of plane bending, 1,4-disubstituted benzene ring), 730 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.22 (s, 1H, --CH=N), 7.93 (m, 4H, 4-chlorophenyl, benzylidene), 7.83 (d, 2H, benzylidene), 7.46 (d, 2H, 4-chlorophenyl), 7.01 (s, 1H, phenylimino), 7.00 (d, 2H, phenylimino), 2.69 (s, 6H, Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.6, 160.3, 151.0, 143.4, 137.3, 136.8, 136.0, 132.0, 130.2, 129.5, 129.1, 127.7, 123.9, 24.3, 15.6 ppm; MS (ES+, ToF): *m*/*z* = 391 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chloro*-*4*-*nitrophenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**6**, C~21~H~14~Cl~2~N~4~O~3~) {#d29e15282}

Yield: 72.0 %; TLC: *R* ~f~ = 0.61; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,650 (C=O str., secondary amide), 1,545 (NO~2~ asym. str., Ar--NO~2~), 1,506 (C=C skeletal str., phenyl nucleus), 839 (C--H out of plane bending, 1,2,4-trisubstituted benzene ring), 818 (C--H out of plane bending, 1,4-disubstituted benzene ring), 730 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.65 (s, 1H, --CH=N), 8.29 (s, 1H, ArClNO~2~), 8.11 (d, 1H, ArClNO~2~), 7.94 (m, 2H, benzylidene), 7.89 (m, 4H, 4-chlorophenyl, benzylidene), 7.59 (d, 1H, ArClNO~2~), 7.45 (d, 2H, 4-chlorophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.4, 160.1, 149.3, 148.4, 143.5, 137.4, 136.3, 132.3, 129.2, 129.0, 128.7, 125.0, 124.1, 120.6 ppm; MS (ES+, ToF): *m*/*z* = 442 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**7**, C~21~H~15~ClN~4~O~3~) {#d29e15398}

Yield: 63.5 %; TLC: *R* ~f~ = 0.69; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,649 (C=O str., secondary amide), 1,548 (asym. str., NO~2~), 1,514 (C=C skeletal str., phenyl nucleus), 814 (C--H out of plane bending, 1,4-disubstituted benzene ring), 752 (C--H out of plane bending, 1,2-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.72 (s, 1H, --CH=N), 8.44 (d, 1H, ArNO~2~), 8.04 (d, 2H, benzylidene), 7.99 (m, 4H, 4-chlorophenyl, benzylidene), 7.70 (m, 1H, ArNO~2~), 7.59 (d, 2H, ArNO~2~), 7.28 (d, 2H, 4-chlorophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 129.6, 129.3, 128.3, 127.5, 119.8, 109.9, 107.3 ppm; MS (ES+, ToF): *m*/*z* = 408 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*chlorobenzoic acid hydrazide* (**8**, C~21~H~15~ClN~4~O~3~) {#d29e15502}

Yield: 66.9 %; TLC: *R* ~f~ = 0.54; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,649 (C=N str., CH=N), 1,632 (C=O str., secondary amide), 1,520 (NO~2~ asym. str., Ar-NO~2~), 812 (C--H out of plane bending, 1,4-disubstituted benzene ring), 738 (C--Cl str., ArCl), 693 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.44 (s, 1H, --CH=N), 8.17 (d, 2H, ArNO~2~), 7.98 (d, 2H, benzylidene), 7.70 (m, 4H, 4-chlorophenyl, benzylidene), 7.60 (d, 2H, ArNO~2~), 7.58 (d, 2H, 4-chlorophenyl), 7.53 (m, 1H, ArNO~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 191.6, 149.5, 139.8, 129.7, 129.4, 128.4, 127.7, 120.1, 110.5, 107.8 ppm; MS (ES+, ToF): *m*/*z* = 408 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Phenylimino)methyl\]benzylidene\]*-*2*-*hydroxybenzoic acid hydrazide* (**9**, C~21~H~17~N~3~O~2~) {#d29e15608}

Yield: 62.6 %; TLC: *R* ~f~ = 0.51; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,650 (C=N str., CH=N), 1,625 (C=O str., secondary amide), 1,585 (C=C skeletal str., phenyl nucleus), 1,359 (C--O str. and O--H in plane bending, phenol), 740 (C--H out of plane bending, 1,2-disubstituted benzene ring), 692 (C--C out of plane bending, monosubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 15.42, 8.44 (s, 1H, --CH=N), 7.96 (d, 2H, benzylidene), 7.83 (d, 1H, 2-hydroxyphenyl), 7.82 (d, 2H, benzylidene), 7.40 (m, 1H, 2-hydroxyphenyl), 7.27 (m, 5H, phenylimino), 7.11 (m, 1H, 2-hydroxyphenyl), 6.94 (d, 1H, 2-hydroxyphenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.2, 160.4, 160.3, 159.1, 153.3, 143.2, 136.3, 133.5, 130.2, 129.8, 129.0, 127.3, 122.0, 121.7, 119.8 ppm; MS (ES+, ToF): *m*/*z* = 344 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chlorophenylimino)methyl\]benzylidene\]*-*2*-*hydroxybenzoic acid hydrazide* (**10**, C~21~H~16~ClN~3~O~2~) {#d29e15695}

Yield: 68.1 %; TLC: *R* ~f~ = 0.67; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,650 (C=N str., CH=N), 1,626 (C=O str., secondary amide), 1,585 (C=C skeletal str., phenyl nucleus), 1,359 (C--O str. and O--H in plane bending, phenol), 740 (C--H out of plane bending, 1,2-disubstituted benzene ring), 695 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.41 (s, 1H, --CH=N), 7.81 (d, 2H, benzylidene), 7.81 (d, 1H, 2-hydroxyphenyl), 7.63 (d, 2H, benzylidene), 7.32 (m, 4H, phenylimino), 7.31 (m, 1H, 2-hydroxyphenyl), 7.10 (m, 1H, 2-hydroxyphenyl), 6.72 (d, 1H, 2-hydroxyphenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 165.3, 159.7, 147.9, 133.8, 129.6, 128.1, 127.6, 127.5, 118.6, 117.3, 114.8 ppm; MS (ES+, ToF): *m*/*z* = 379 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(4*-*Nitrophenylimino)methyl\]benzylidene\]*-*2*-*hydroxybenzoic acid hydrazide* (**11**, C~21~H~16~N~4~O~4~) {#d29e15785}

Yield: 69.3 %; TLC: *R* ~f~ = 0.56; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,626 (C=O str., secondary amide), 1,546 (asym. str., NO~2~), 1,492 (C=C skeletal str., phenyl nucleus), 1,360 (C--O str. and O--H in plane bending, phenol), 829 (C--H out of plane bending, 1,4-disubstituted benzene ring), 740 (C--H out of plane bending, 1,2-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.43 (s, 1H, --CH=N), 8.22 (d, 2H, phenylimino), 8.00 (d, 2H, benzylidene), 7.93 (d, 2H, benzylidene), 7.80 (d, 1H, 2-hydroxyphenyl), 7.51 (d, 2H, phenylimino), 7.44 (m, 1H, 2-hydroxyphenyl), 7.00 (m, 1H, 2-hydroxyphenyl), 6.97 (d, 1H, 2-hydroxyphenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.0, 160.7, 160.2, 159.3, 159.1, 146.9, 143.3, 136.5, 133.8, 129.9, 129.2, 123.5, 122.2, 121.5, 119.5 ppm; MS (ES+, ToF): *m*/*z* = 389 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,5*-*Dimethylphenylimino)methyl\]benzylidene\]*-*2*-*hydroxybenzoic acid hydrazide* (**12**, C~23~H~21~N~3~O~2~) {#d29e15878}

Yield: 62.2 %; TLC: *R* ~f~ = 0.63; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,650 (C=N str., CH=N), 1,626 (C=O str., secondary amide), 1,584 (C=C skeletal str., phenyl nucleus), 1,370 (C--O str. and O--H in plane bending, phenol), 740 (C--H out of plane bending, 1,2-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 9.84 (s, 1H, phenylimino), 8.28 (s, 1H, --CH=N), 7.93 (d, 2H, benzylidene), 7.85 (d, 2H, benzylidene), 7.81 (d, 1H, 2-hydroxyphenyl), 7.46 (m, 1H, 2-hydroxyphenyl), 7.01 (m, 1H, 2-hydroxyphenyl), 7.00 (d, 2H, phenylimino), 6.94 (d, 1H, 2-hydroxyphenyl), 2.68 (s, 6H, Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.1, 160.4, 159.2, 151.2, 136.7, 133.6, 130.1, 129.9, 127.8, 123.5, 121.7, 119.6, 24.2, 15.8 ppm; MS (ES+, ToF): *m*/*z* = 372 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Phenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**13**, C~21~H~18~N~4~O) {#d29e15974}

Yield: 61.0 %; TLC: *R* ~f~ = 0.72; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,707 (C=N str., CH=N), 1,616 (C=O str., secondary amide), 1,584 (C=C skeletal str., phenyl nucleus), 1,310 (C--N str., Ar--NH~2~), 829 (C--H out of plane bending, 1,4-disubstituted benzene ring), 693 (C--H out of plane bending, monosubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.67 (s, 1H, --CH=N), 8.10 (d, 2H, benzylidene), 7.92 (d, 2H, benzylidene), 7.59 (d, 2H, 4-aminophenyl), 7.33 (m, 5H, phenylimino), 6.99 (d, 2H, 4-aminophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 160.0, 153.3, 151.6, 143.1, 136.1, 130.1, 129.2, 128.3, 127.0, 124.1, 122.4, 116.0 ppm; MS (ES+, ToF): *m*/*z* = 343 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**14**, C~21~H~17~ClN~4~O) {#d29e16061}

Yield: 73.8 %; TLC: *R* ~f~ = 0.55; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,675 (C=N str., CH=N), 1,624 (C=O str., secondary amide), 1,584 (C=C skeletal str., phenyl nucleus), 1,303 (C--N str., Ar-NH~2~), 837 (C--H out of plane bending, 1,4-disubstituted benzene ring), 730 (C--Cl str., ArCl), 682 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.68 (s, 1H, --CH=N), 7.93 (d, 2H, benzylidene), 7.80 (d, 2H, benzylidene), 7.74 (d, 2H, 4-aminophenyl), 7.34 (s, 1H, phenylimino), 7.26 (d, 2H, phenylimino), 7.02 (m, 1H, phenylimino), 6.64 (d, 2H, 4-aminophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.1, 160.3, 154.6, 151.8, 143.1, 136.0, 135.9, 131.7, 129.1, 128.4, 127.3, 124.2, 122.7, 120.2, 116.2 ppm; MS (ES+, ToF): *m*/*z* = 378 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,4*-*Dimethylphenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**15**, C~23~H~22~N~4~O) {#d29e16151}

Yield: 49.7 %; TLC: *R* ~f~ = 0.67; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,706 (C=N str., CH=N), 1,623 (C=O str., secondary amide), 1,592 (C=C skeletal str., phenyl nucleus), 1,308 (C--N str., Ar-NH~2~), 884 (C--H out of plane bending, 1,2,4-trisubstituted benzene ring), 802 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.57 (s, 1H, --CH=N), 7.93 (d, 2H, benzylidene), 7.72 (d, 2H, 4-aminophenyl), 7.72 (d, 2H, benzylidene), 7.10 (d, 2H, phenylimino), 6.94 (s, 1H, phenylimino), 6.68 (d, 2H, 4-aminophenyl), 2.37 (s, 6H, Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 160.5, 160.2, 151.6, 148.2, 143.2, 136.6, 136.2, 132.4, 130.7, 129.4, 128.2, 127.0, 124.0, 116.3, 112.2, 24.8 ppm; MS (ES+, ToF): *m*/*z* = 371 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,5*-*Dimethylphenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**16**, C~23~H~22~N~4~O) {#d29e16248}

Yield: 66.2 %; TLC: *R* ~f~ = 0.69; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,677 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,571 (C=C skeletal str., phenyl nucleus), 1,292 (C--N str., Ar-NH~2~), 804 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.52 (s, 1H, --CH=N), 7.93 (d, 2H, benzylidene), 7.82 (d, 2H, benzylidene), 7.72 (d, 2H, 4-aminophenyl), 6.99 (d, 2H, phenylimino), 6.94 (s, 1H, phenylimino), 6.86 (d, 2H, 4-aminophenyl), 2.37 (s, 6H, Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 158.8, 149.9, 138.5, 135.8, 129.3, 128.8, 128.4, 126.5, 118.2 ppm; MS (ES+, ToF): *m*/*z* = 371 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Phenylimino)methyl\]benzylidene\]*-*4*-*methylbenzoic acid hydrazide* (**17**, C~22~H~19~N~3~O) {#d29e16345}

Yield: 64.0 %; TLC: *R* ~f~ = 0.38; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,690 (C=N str., CH=N), 1,617 (C=O str., secondary amide), 1,507 (C=C skeletal str., phenyl nucleus), 827 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.42 (s, 1H, --N=CH), 7.98 (d, 2H, benzylidene), 7.86 (d, 2H, 4-methylbenzohydrazide), 7.83 (d, 2H, benzylidene), 7.65 (m, 5H, phenylimino), 7.22 (d, 2H, 4-methylbenzohydrazide) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.2, 160.2, 153.5, 143.1, 141.4, 136.3, 130.3, 129.5, 129.4, 127.6, 127.5, 122.4, 24.6 ppm; MS (ES+, ToF): *m*/*z* = 342 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*methylbenzoic acid hydrazide* (**18**, C~22~H~18~ClN~3~O) {#d29e16429}

Yield: 68.4 %; TLC: *R* ~f~ = 0.73; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,646 (C=N str., CH=N), 1,611 (C=O str., secondary amide), 1,502 (C=C skeletal str., phenyl nucleus), 830 (C--H out of plane bending, 1,4-disubstituted benzene ring), 745 (C--H out of plane bending, 1,2-disubstituted benzene ring), 704 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 7.96 (s, 1H, --CH=N), 7.94 (d, 2H, benzylidene), 7.90 (d, 2H, benzylidene), 7.88 (d, 2H, 4-methylbenzohydrazide), 7.40 (d, 2H, 4-methylbenzohydrazide), 7.40 (d, 3H, phenylimino), 7.22 (m, 1H, phenylimino), 2.46 (s, 3H, ArCH~3~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.0, 160.2, 143.4, 143.4, 141.1, 136.5, 130.5, 129.7, 129.3, 128.7, 127.5, 127.4, 124.7, 12.5 ppm; MS (ES+, ToF): *m*/*z* = 377 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,4*-*Dimethylphenylimino)methyl\]benzylidene\]*-*4*-*methylbenzoic acid hydrazide* (**19**, C~24~H~23~N~3~O) {#d29e16520}

Yield: 61.7 %; TLC: *R* ~f~ = 0.50; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,652 (C=N str., CH=N), 1,630 (C=O str., secondary amide), 1,505 (C=C skeletal str., phenyl nucleus), 917 (C--H out of plane bending, 1,2,4-trisubstituted benzene ring), 832 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.00 (s, 1H, --N=CH), 7.99 (d, 2H, benzylidene), 7.87 (d, 2H, 4-methylbenzohydrazide), 7.86 (d, 2H, benzylidene), 7.39 (d, 2H, 4-methylbenzohydrazide), 6.84 (d, 2H, phenylimino), 6.08 (s, 1H, phenylimino), 2.36 (s, 6H, --Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 160.5, 160.4, 148.3, 143.6, 141.0, 136.8, 136.7, 132.3, 130.7, 129.5, 129.4, 127.4, 127.2, 122.2, 24.9 ppm; MS (ES+, ToF): *m*/*z* = 370 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Chlorophenylimino)methyl\]benzylidene\]*-*3*-*methylbenzoic acid hydrazide* (**20**, C~22~H~18~ClN~3~O) {#d29e16613}

Yield: 62.3 %; TLC: *R* ~f~ = 0.82; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,656 (C=N str., CH=N), 1,619 (C=O str., secondary amide), 1,506 (C=C skeletal str., phenyl nucleus), 732 (C--Cl str., ArCl), 682 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.00 (s, 1H, --CH=N), 7.96 (d, 1H, 3-methylbenzohydrazide), 7.96 (d, 2H, benzylidene), 7.81 (d, 2H, benzylidene), 7.78 (s, 1H, 3-methylbenzohydrazide), 7.46 (d, 1H, 3-methylbenzohydrazide), 7.33 (s, 1H, phenylimino), 7.29 (m, 1H, phenylimino), 7.21 (d, 2H, phenylimino), 7.03 (m, 1H, 3-methylbenzohydrazide), 2.47 (s, 3H, ArCH~3~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.4, 160.7, 154.6, 143.1, 138.3, 136.6, 135.5, 134.2, 132.7, 131.2, 129.8, 128.5, 127.5, 127.4, 124.6, 122.8, 120.3, 24.7 ppm; MS (ES+, ToF): *m*/*z* = 377 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Phenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**21**, C~21~H~17~N~3~O~2~) {#d29e16703}

Yield: 65.7 %; TLC: *R* ~f~ = 0.64; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,697 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,584 (C=C skeletal str., phenyl nucleus), 1,388 (C--O str. and O--H in plane bending, phenol), 827 (C--H out of plane bending, 1,4-disubstituted benzene ring), 691 (C--C out of plane bending, monosubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.09 (s, 1H, --CH=N), 7.95 (d, 2H, benzylidene), 7.85 (d, 2H, benzylidene), 7.79 (d, 2H, 4-hydroxybenzohydrazide), 7.32 (m, 5H, phenylimino), 6.85 (d, 2H, 4-hydroxybenzohydrazide) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.2, 161.6, 160.3, 153.2, 143.3, 136.2, 130.3, 129.4, 128.7, 128.5, 127.5, 122.4, 116.2 ppm; MS (ES+, ToF): *m*/*z* = 344 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**22**, C~21~H~16~ClN~3~O~2~) {#d29e16790}

Yield: 78.2 %; TLC: *R* ~f~ = 0.62; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,687 (C=N str., CH=N), 1,620 (C=O str., secondary amide), 1,576 (C=C skeletal str., phenyl nucleus), 1,392 (C--O str. and O--H in plane bending, phenol), 817 (C--H out of plane bending, 1,4-disubstituted benzene ring), 772 (C--H out of plane bending, 1,2-disubstituted benzene ring), 718 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.37 (s, 1H, --CH=N), 7.93 (d, 2H, benzylidene), 7.81 (d, 2H, benzylidene), 7.76 (d, 2H, 4-hydroxybenzohydrazide), 7.33 (m, 3H, phenylimino), 7.22 (m, 1H, phenylimino), 6.84 (d, 2H, 4-hydroxybenzohydrazide) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.0, 161.3, 160.4, 151.4, 143.4, 143.1, 136.9, 136.3, 130.3, 130.2, 129.5, 128.6, 128.6, 128.6, 127.8, 127.5, 123.9, 123.3, 116.0, 24.2, 15.8 ppm; MS (ES+, ToF): *m*/*z* = 379 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2,5*-*Dimethylphenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**23**, C~23~H~21~N~3~O~2~) {#d29e16880}

Yield: 81.5 %; TLC: *R* ~f~ = 0.57; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,688 (C=N str., CH=N), 1,620 (C=O str., secondary amide), 1,576 (C=C skeletal str., phenyl nucleus), 1,391 (C--O str. and O--H in plane bending, phenol), 824 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.01 (s, 1H, --CH=N), 7.91 (d, 2H, benzylidene), 7.85 (d, 2H, benzylidene), 7.76 (d, 2H, 4-hydroxybenzohydrazide), 7.48 (d, 2H, 4-hydroxybenzohydrazide), 7.32 (d, 2H, phenylimino), 7.02 (s, 1H, phenylimino), 2.36 (s, 6H, --Ar(CH~3~)~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.2, 161.5, 160.1, 143.5, 136.1, 129.7, 128.7, 128.4, 116.2 ppm; MS (ES+, ToF): *m*/*z* = 372 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chlorophenylimino)methyl\]benzylidene\]*-*3*-*nitrobenzoic acid hydrazide* (**24**, C~21~H~15~ClN~4~O~3~) {#d29e16976}

Yield: 84.0 %; TLC: *R* ~f~ = 0.81; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,650 (C=N str., CH=N), 1,614 (C=O str., secondary amide), 1,550 (asym. str., NO~2~), 1,504 (C=C skeletal str., phenyl nucleus), 768 (C--H out of plane bending, 1,2-disubstituted benzene ring), 753 (C--Cl str., ArCl), 721 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.92 (s, 1H, 3-nitrobenzohydrazide), 8.61 (d, 1H, 3-nitrobenzohydrazide), 8.54 (d, 1H, 3-nitrobenzohydrazide), 8.44 (s, 1H, --CH=N), 7.95 (d, 2H, benzylidene), 7.89 (m, 1H, 3-nitrobenzohydrazide), 7.63 (d, 2H, benzylidene), 7.36 (m, 3H, phenylimino), 7.21 (m, 1H, phenylimino) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.2, 160.2, 148.6, 143.3, 143.1, 136.3, 135.2, 133.9, 130.4, 129.9, 129.4, 128.7, 127.5, 124.1, 123.3, 122.5 ppm; MS (ES+, ToF): *m*/*z* = 408 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(4*-*Chlorophenylimino)methyl\]benzylidene\]*-*3*-*nitrobenzoic acid hydrazide* (**25**, C~21~H~15~ClN~4~O~3~) {#d29e17069}

Yield: 76.7 %; TLC: *R* ~f~ = 0.54; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,651 (C=N str., CH=N), 1,614 (C=O str., secondary amide), 1,552 (asym. str., NO~2~), 1,506 (C=C skeletal str., phenyl nucleus), 815 (C--H out of plane bending, 1,4-disubstituted benzene ring), 721 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.90 (s, 1H, 3-nitrobenzohydrazide), 8.43 (d, 1H, 3-nitrobenzohydrazide), 8.42 (s, 1H, --CH=N), 8.07 (d, 1H, 3-nitrobenzohydrazide), 7.97 (d, 2H, benzylidene), 7.82 (m, 1H, 3-nitrobenzohydrazide), 7.61 (d, 2H, benzylidene), 7.31 (d, 2H, phenylimino), 7.19 (d, 2H, phenylimino) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 160.0, 151.0, 148.9, 143.1, 136.0, 135.3, 133.8, 132.6, 130.1, 129.7, 129.5, 124.2, 123.8, 122.6 ppm; MS (ES+, ToF): *m*/*z* = 408 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Phenylimino)methyl\]benzylidene\]*-*4*-*nitrobenzoic acid hydrazide* (**26**, C~21~H~16~N~4~O~3~) {#d29e17162}

Yield: 69.3 %; TLC: *R* ~f~ = 0.70; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,657 (C=N str., CH=N), 1,561 (asym. str., NO~2~), 1,516 (C=C skeletal str., phenyl nucleus), 820 (C--H out of plane bending, 1,4-disubstituted benzene ring), 702 (C--C out of plane bending, monosubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.42 (d, 2H, 4-nitrobenzohydrazide), 8.42 (s, 1H, --CH=N), 8.19 (d, 2H, 4-nitrobenzohydrazide), 8.01 (d, 2H, benzylidene), 7.89 (d, 2H, benzylidene), 7.19 (m, 5H, phenylimino) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 161.9, 149.8, 141.8, 129.6, 129.0, 128.8, 127.5, 123.3, 122.6, 121.2 ppm; MS (ES+, ToF): *m*/*z* = 373 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*nitrobenzoic acid hydrazide* (**27**, C~21~H~15~ClN~4~O~3~) {#d29e17252}

Yield: 67.4 %; TLC: *R* ~f~ = 0.78; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,657 (C=N str., CH=N), 1,562 (asym. str., NO~2~), 1,515 (C=C skeletal str., phenyl nucleus), 821 (C--H out of plane bending, 1,4-disubstituted benzene ring), 702 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.57 (s, 1H, --N=CH), 8.32 (d, 2H, 4-nitrobenzohydrazide), 8.01 (d, 2H, 4-nitrobenzohydrazide), 8.00 (d, 2H, benzylidene), 7.76 (d, 2H, benzylidene), 7.38 (m, 3H, phenylimino), 7.22 (m, 1H, phenylimino) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 162.1, 148.9, 143.1, 135.3, 133.8, 129.8, 129.7, 129.2, 124.2, 123.4, 122.6 ppm; MS (ES+, ToF): *m*/*z* = 408 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(4*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**28**, C~21~H~17~N~5~O~3~) {#d29e17345}

Yield: 83.2 %; TLC: *R* ~f~ = 0.42; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,689 (C=N str., CH=N), 1,619 (C=O str., secondary amide), 1,505 (asym. str., NO~2~), 1,275 (C--N str., Ar--NH~2~), 823 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.33 (s, 1H, --N=CH), 8.12 (d, 2H, phenylimino), 7.89 (d, 2H, benzylidene), 7.84 (d, 2H, benzylidene), 7.70 (d, 2H, 4-aminophenyl), 7.60 (d, 2H, phenylimino), 6.66 (d, 2H, 4-aminophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.4, 160.1, 159.5, 151.8, 146.8, 143.2, 136.0, 129.3, 128.4, 124.0, 123.4, 123.3, 122.7, 122.5, 116.1 ppm; MS (ES+, ToF): *m*/*z* = 388 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(4*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**29**, C~21~H~17~ClN~4~O) {#d29e17441}

Yield: 66.7 %; TLC: *R* ~f~ = 0.44; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,700 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,274 (C--N str., Ar--NH~2~), 828 (C--H out of plane bending, 1,4-disubstituted benzene ring), 729 (C--Cl str., ArCl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.33 (s, 1H, --N=CH), 8.12 (d, 2H, phenylimino), 7.98 (d, 2H, benzylidene), 7.83 (d, 2H, benzylidene), 7.74 (d, 2H, 4-aminophenyl), 7.60 (d, 2H, phenylimino), 6.64 (d, 2H, 4-aminophenyl), 4.31 (s, 2H, --ArNH~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.7, 160.4, 151.5, 151.5, 143.5, 136.0, 132.6, 130.4, 130.3, 129.1, 128.6, 124.3, 123.9, 123.5, 116.4 ppm; MS (ES+, ToF): *m*/*z* = 378 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**30**, C~21~H~17~N~5~O~3~) {#d29e17535}

Yield: 67.4 %; TLC: *R* ~f~ = 0.53; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,698 (C=N str., CH=N), 1,619 (C=O str., secondary amide), 1,524 (asym. str., NO~2~), 1,274 (C--N str., Ar--NH~2~), 826 (C--H out of plane bending, 1,4-disubstituted benzene ring), 697 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.42 (s, 1H, --N=CH), 8.31 (s, 1H, phenylimino), 8.11 (d, 1H, phenylimino), 7.99 (d, 2H, benzylidene), 7.85 (d, 2H, benzylidene), 7.79 (d, 1H, phenylimino), 7.78 (d, 2H, 4-aminophenyl), 7.50 (m, 1H, phenylimino), 6.67 (d, 2H, 4-aminophenyl), 4.29 (s, 2H, --NH~2~ of ArNH~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.1, 160.3, 154.3, 151.6, 149.6, 143.3, 136.1, 131.2, 129.4, 128.7, 128.0, 124.2, 119.9, 117.3, 116.3 ppm; MS (ES+, ToF): *m*/*z* = 388 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**31**, C~21~H~17~N~5~O~3~) {#d29e17638}

Yield: 60.5 %; TLC: *R* ~f~ = 0.56; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,697 (C=N str., CH=N), 1,619 (C=O str., secondary amide), 1,504 (asym. str., NO~2~), 1,275 (C--N str., Ar--NH~2~), 826 (C--H out of plane bending, 1,4-disubstituted benzene ring), 744 (C--H out of plane bending, 1,2-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.52 (d, 2H, phenylimino), 8.26 (s, 1H, --N=CH), 8.11 (d, 1H, phenylimino), 7.98 (d, 2H, benzylidene), 7.85 (d, 2H, benzylidene), 7.79 (m, 1H, phenylimino), 7.77 (d, 2H, 4-aminophenyl), 7.38 (m, 1H, phenylimino), 6.66 (d, 2H, 4-aminophenyl), 4.32 (s, 2H, --NH~2~ of ArNH~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.0, 160.0, 151.8, 148.5, 143.5, 141.8, 136.4, 136.3, 129.6, 128.3, 128.2, 124.0, 123.3, 122.6, 116.5 ppm; MS (ES+, ToF): *m*/*z* = 388 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Methyl*-*5*-*nitrophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**32**, C~22~H~19~N~5~O~3~) {#d29e17741}

Yield: 40.6 %; TLC: *R* ~f~ = 0.54; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,701 (C=N str., CH=N), 1,623 (C=O str., secondary amide), 1,509 (asym. str., NO~2~), 1,270 (C--N str., Ar--NH~2~), 829 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.46 (s, 1H, --N=CHAr), 8.32 (d, 1H, phenylimino), 8.21 (d, 2H, phenylimino), 7.93 (d, 2H, benzylidene), 7.83 (d, 2H, benzylidene), 7.72 (d, 2H, 4-aminophenyl), 6.64 (d, 2H, 4-aminophenyl), 2.07 (s, 3H, --ArCH~3~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.1, 160.4, 152.4, 151.3, 146.9, 143.6, 136.7, 136.0, 131.6, 129.5, 128.0, 124.1, 119.4, 117.2, 116.3, 15.5 ppm; MS (ES+, ToF): *m*/*z* = 402 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chloro*-*4*-*nitrophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**33**, C~21~H~16~ClN~5~O~3~) {#d29e17848}

Yield: 63.7 %; TLC: *R* ~f~ = 0.36; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,703 (C=N str., CH=N), 1,620 (C=O str., secondary amide), 1,505 (asym. str., NO~2~), 1,272 (C--N str., Ar--NH~2~), 885 (C--H out of plane bending, 1,2,4-trisubstituted benzene ring), 828 (C--H out of plane bending, 1,4-disubstituted benzene ring), 723 (C--Cl str., Ar--Cl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.65 (s, 1H, --CH=N), 8.22 (s, 1H, phenylimino), 8.11 (d, 1H, phenylimino), 8.05 (d, 2H, benzylidene), 7.84 (d, 2H, benzylidene), 7.76 (d, 2H, 4-aminophenyl), 7.55 (d, 1H, phenylimino), 6.65 (d, 2H, 4-aminophenyl), 4.31 (s, 2H, --ArNH~2~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.5, 160.5, 151.1, 149.5, 148.6, 143.8, 136.1, 129.3, 128.9, 128.2, 125.4, 124.7, 124.5, 120.4, 116.4 ppm; MS (ES+, ToF): *m*/*z* = 423 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**34**, C~21~H~16~ClN~3~O~2~) {#d29e17955}

Yield: 60.9 %; TLC: *R* ~f~ = 0.57; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,699 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,581 (C=C skeletal str., phenyl nucleus), 1,390 (C--O str. and O--H in plane bending, phenol), 826 (C--H out of plane bending, 1,4-disubstituted benzene ring), 710 (C--Cl str., Ar--Cl), 683 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.65 (s, 1H, --CH=N), 7.98 (d, 2H, benzylidene), 7.89 (m, 1H, benzylidene), 7.76 (d, 2H, 4-hydroxyphenyl), 7.55 (s, 1H, phenylimino), 7.21 (d, 2H, phenylimino), 7.12 (d, 1H, phenylimino), 6.84 (d, 2H, 4-hydroxyphenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.6, 161.7, 160.5, 154.9, 143.4, 136.6, 135.8, 131.6, 129.0, 128.9, 128.5, 127.6, 122.9, 120.7, 116.3 ppm; MS (ES+, ToF): *m*/*z* = 379 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**35**, C~21~H~16~N~4~O~4~) {#d29e18045}

Yield: 65.6 %; TLC: *R* ~f~ = 0.38; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,699 (C=N str., CH=N), 1,620 (C=O str., secondary amide), 1,511 (asym. str., NO~2~), 1,391 (C--O str. and O--H in plane bending, phenol), 828 (C--H out of plane bending, 1,4-disubstituted benzene ring), 754 (C--H out of plane bending, 1,2-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.22 (s, 1H, --N=CH), 8.00 (d, 1H, phenylimino), 7.88 (d, 2H, benzylidene), 7.77 (m, 1H, benzylidene), 7.77 (m, 1H, phenylimino), 7.62 (d, 2H, 4-hydroxyphenyl), 7.53 (m, 2H, phenylimino), 6.64 (d, 2H, 4-hydroxyphenyl), 5.22 (s, 1H, --ArOH) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.9, 161.8, 160.2, 148.8, 148.6, 143.7, 136.9, 136.3, 129.4, 128.8, 128.4, 128.4, 123.5, 122.4, 116.4 ppm; MS (ES+, ToF): *m*/*z* = 389 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(4*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**36**, C~21~H~16~N~4~O~4~) {#d29e18138}

Yield: 79.0 %; TLC: *R* ~f~ = 0.59; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,695 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,506 (asym. str., NO~2~), 1,345 (C--O str. and O--H in plane bending, phenol), 823 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.35 (s, 1H, --N=CH), 8.06 (d, 2H, phenylimino), 7.99 (d, 2H, benzylidene), 7.89 (m, 1H, benzylidene), 7.70 (d, 2H, 4-hydroxyphenyl), 7.50 (d, 2H, phenylimino), 6.63 (d, 2H, 4-hydroxyphenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 161.8, 160.4, 159.4, 146.8, 143.2, 136.4, 136.3, 129.7, 129.5, 129.5, 129.2, 128.8, 128.7, 126.6, 123.5, 123.4, 122.7, 122.6, 116.4, 116.3 ppm; MS (ES+, ToF): *m*/*z* = 389 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Chloro*-*4*-*nitrophenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**37**, C~21~H~15~ClN~4~O~4~) {#d29e18231}

Yield: 61.4 %; TLC: *R* ~f~ = 0.51; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,696 (C=N str., CH=N), 1,619 (C=O str., secondary amide), 1,506 (asym. str., NO~2~), 1,391 (C--O str. and O--H in plane bending, phenol), 874 (C--H out of plane bending, 1,2,4-trisubstituted benzene ring), 825 (C--H out of plane bending, 1,4-disubstituted benzene ring), 745 (C--Cl str., Ar--Cl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.48 (s, 1H, --CH=N), 8.13 (s, 1H, phenylimino), 8.01 (d, 1H, phenylimino), 7.89 (d, 2H, benzylidene), 7.80 (m, 1H, benzylidene), 7.72 (d, 2H, 4-hydroxyphenyl), 7.62 (d, 1H, phenylimino), 6.65 (d, 2H, 4-hydroxyphenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.6, 161.6, 160.0, 149.7, 148.5, 143.5, 136.8, 129.3, 128.9, 128.9, 128.6, 125.3, 124.8, 120.9, 116.8 ppm; MS (ES+, ToF): *m*/*z* = 424 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Nitrophenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**38**, C~21~H~16~N~4~O~4~) {#d29e18331}

Yield: 80.0 %; TLC: *R* ~f~ = 0.40; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,698 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,524 (asym. str., NO~2~), 1,389 (C--O str. and O--H in plane bending, phenol), 825 (C--H out of plane bending, 1,4-disubstituted benzene ring), 697 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.41 (s, 1H, --N=CH), 8.23 (s, 1H, phenylimino), 8.22 (d, 1H, phenylimino), 7.89 (d, 2H, benzylidene), 7.84 (d, 1H, phenylimino), 7.80 (m, 1H, benzylidene), 7.72 (d, 2H, 4-hydroxyphenyl), 7.51 (m, 1H, phenylimino), 6.65 (d, 2H, 4-hydroxyphenyl), 5.23 (s, 1H, --ArOH) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.3, 161.5, 160.2, 154.3, 149.8, 143.2, 136.6, 129.5, 129.4, 128.7, 128.6, 128.4, 119.9, 117.3, 116.9 ppm; MS (ES+, ToF): *m*/*z* = 389 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(4*-*Chlorophenylimino)methyl\]benzylidene\]*-*4*-*hydroxybenzoic acid hydrazide* (**39**, C~21~H~16~ClN~3~O~2~) {#d29e18424}

Yield: 82.7 %; TLC: *R* ~f~ = 0.42; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,698 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,508 (C=C skeletal str., phenyl), 1,390 (C--O str. and O--H in plane bending, phenol), 826 (C--H out of plane bending, 1,4-disubstituted benzene ring), 730 (C--Cl str., Ar--Cl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.10 (s, 1H, CH=N), 7.91 (d, 2H, benzylidene), 7.89 (m, 1H, benzylidene), 7.76 (d, 2H, 4-hydroxyphenyl), 7.34 (d, 2H, phenylimino), 7.26 (d, 2H, phenylimino), 6.86 (d, 2H, 4-hydroxyphenyl), 5.50 (s, 1H, --ArOH) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.9, 161.4, 160.4, 151.5, 143.8, 136.4, 132.6, 130.5, 130.4, 129.7, 128.9, 128.8, 123.9, 123.4, 116.5 ppm; MS (ES+, ToF): *m*/*z* = 379 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(4*-*Chlorophenylimino)methyl\]benzylidene\]*-*2*-*hydroxybenzoic acid hydrazide* (**40**, C~21~H~16~ClN~3~O~2~) {#d29e18514}

Yield: 70.5 %; TLC: *R* ~f~ = 0.60; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,652 (C=N str., CH=N), 1,619 (C=O str., secondary amide), 1,377 (C--O str. and O--H in plane bending, phenol), 827 (C--H out of plane bending, 1,4-disubstituted benzene ring), 738 (C--H out of plane bending, 1,2-disubstituted benzene ring), 691 (C--Cl str., Ar--Cl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.44 (s, 1H, --CH=N), 7.91 (d, 2H, benzylidene), 7.89 (m, 1H, benzylidene), 7.65 (d, 1H, 2-hydroxyphenyl), 7.35 (m, 1H, 2-hydroxyphenyl), 7.30 (d, 2H, phenylimino), 7.22 (d, 2H, phenylimino), 7.00 (m, 1H, 2-hydroxyphenyl), 6.89 (d, 1H, 2-hydroxyphenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.2, 160.6, 160.5, 159.0, 151.4, 143.4, 136.5, 133.7, 132.6, 130.5, 130.0, 129.6, 129.2, 123.9, 123.5, 121.8, 119.5 ppm; MS (ES+, ToF): *m*/*z* = 379 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Fluorophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**41**, C~21~H~17~FN~4~O) {#d29e18605}

Yield: 62.3 %; TLC: *R* ~f~ = 0.48; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,698 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,508 (C=C skeletal str., phenyl), 1,297 (C--N str., Ar--NH~2~), 1,013 (C--F str., Ar--F), 828 (C--H out of plane bending, 1,4-disubstituted benzene ring), 698 (C--C out of plane bending, 1,3-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.44 (s, 1H, --CH=N), 7.93 (d, 2H, benzylidene), 7.82 (d, 2H, benzylidene), 7.61 (d, 2H, 4-aminophenyl), 7.29 (s, 1H, phenylimino), 7.01 (d, 2H, phenylimino), 7.01 (m, 1H, phenylimino), 6.67 (d, 2H, 4-aminophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 164.4, 163.4, 160.5, 154.9, 151.8, 143.9, 136.2, 131.6, 129.7, 128.3, 124.0, 117.7, 116.5, 114.3, 109.5 ppm; MS (ES+, ToF): *m*/*z* = 361 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(3*-*Chloro*-*4*-*fluorophenylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**42**, C~21~H~16~ClFN~4~O) {#d29e18695}

Yield: 69.1 %; TLC: *R* ~f~ = 0.58; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,696 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,503 (skeletal str., phenyl), 1,297 (C--N str., Ar--NH~2~), 1,014 (C--F str., Ar--F), 827 (C--H out of plane bending, 1,4-disubstituted benzene ring), 728 (C--Cl str., Ar--Cl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.12 (s, 1H, --CH=N), 7.94 (d, 2H, benzylidene), 7.82 (d, 2H, benzylidene), 7.80 (d, 2H, 4-aminophenyl), 7.29 (s, 1H, phenylimino), 7.01 (d, 1H, phenylimino), 6.73 (d, 1H, phenylimino), 6.69 (d, 2H, 4-aminophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.7, 161.5, 160.6, 151.6, 150.4, 143.7, 136.4, 129.9, 128.1, 124.4, 124.3, 122.3, 122.2, 118.3, 116.2 ppm; MS (ES+, ToF): *m*/*z* = 396 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Butylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**43**, C~19~H~22~N~4~O) {#d29e18791}

Yield: 71.5 %; TLC: *R* ~f~ = 0.58; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,697 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,509 (skeletal str., phenyl), 1,463 (CH~3~ asym. bending, R--CH~3~), 1,297 (C--N str., Ar--NH~2~), 827 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.09 (s, 1H, CH=N), 7.98 (d, 2H, benzylidene), 7.81 (d, 2H, benzylidene), 7.76 (d, 2H, 4-aminophenyl), 6.77 (d, 2H, 4-aminophenyl), 3.52 (t, 2H, --C~4~H~9~), 1.58 (m, 2H, --C~4~H~9~), 1.32 (m, 2H, --C~4~H~9~), 0.93 (t, 3H, --C~4~H~9~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.9, 160.3, 151.7, 143.5, 136.5, 129.8, 128.3, 124.1, 116.4, 55.9, 33.8, 20.1, 13.6 ppm; MS (ES+, ToF): *m*/*z* = 323 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Benzylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**44**, C~22~H~20~N~4~O) {#d29e18910}

Yield: 63.3 %; TLC: *R* ~f~ = 0.62; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,696 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,509 (skeletal str., phenyl), 1,297 (C--N str., Ar--NH~2~), 828 (C--H out of plane bending, 1,4-disubstituted benzene ring), 731 (C--H out of plane bending, monosubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.18 (s, 1H, --CH=N), 7.94 (d, 2H, benzylidene), 7.68 (d, 2H, benzylidene), 7.68 (d, 2H, phenylimino), 7.35 (d, 2H, 4-aminophenyl), 7.24 (d, 2H, phenylimino), 7.11 (m, 1H, phenylimino), 6.82 (d, 2H, 4-aminophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.6, 160.4, 151.8, 143.6, 138.7, 136.6, 129.9, 129.3, 129.2, 128.8, 128.6, 128.5, 125.5, 124.0, 116.6, 58.5 ppm; MS (ES+, ToF): *m*/*z* = 357 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(2*-*Hydroxyethylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**45**, C~17~H~18~N~4~O~2~) {#d29e18997}

Yield: 66.4 %; TLC: *R* ~f~ = 0.54; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,667 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,510 (skeletal str., phenyl), 1,297 (C--N str., Ar--NH~2~), 1,279 (C--O str. and O--H in plane bending, primary alcohol), 828 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.19 (s, 1H, --CH=N), 7.96 (d, 2H, benzylidene), 7.81 (d, 2H, benzylidene), 7.78 (d, 2H, 4-aminophenyl), 6.67 (d, 2H, 4-aminophenyl), 3.86 (m, 2H, N-C~2~H~4~OH), 2.08 (t, 1H, --N--C~2~H~4~OH) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.7, 160.4, 151.5, 143.6, 136.6, 129.7, 128.5, 124.3, 116.6, 64.3, 59.0 ppm; MS (ES+, ToF): *m*/*z* = 311 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Hydroxyimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**46**, C~15~H~14~N~4~O~2~) {#d29e19103}

Yield: 64.2 %; TLC: *R* ~f~ = 0.54; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,692 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,508 (C=C skeletal str., phenyl nucleus), 1,321 (C--N str., Ar--NH~2~), 1,297 (C=O str. and O--H in-plane bending, primary alcohol), 829 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 8.01 (s, 1H, --CH=N), 7.93 (d, 2H, benzylidene), 7.77 (d, 2H, benzylidene), 7.75 (d, 2H, 4-aminophenyl), 6.65 (d, 2H, 4-aminophenyl), 2.07 (s, 1H, --N--OH) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.6, 151.1, 148.0, 143.7, 136.6, 136.4, 129.5, 129.4, 129.3, 129.3, 128.5, 124.1, 116.3 ppm; MS (ES+, ToF): *m*/*z* = 283 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Naphthalen*-*1*-*ylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**47**, C~25~H~20~N~4~O) {#d29e19193}

Yield: 67.3 %; TLC: *R* ~f~ = 0.64; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,696 (C=N str., CH=N), 1,617 (C=O str., secondary amide), 1,514 (C=C skeletal str., phenyl nucleus), 1,321 (C--N str., Ar--NH~2~), 826 (C--H out of plane bending, 1,4-disubstituted benzene ring), 771 (C--H out of plane bending, 1-naphthalenyl) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 7.99 (s, 1H, --CH=N), 7.96 (d, 2H, benzylidene), 7.77 (d, 2H, naphthalene), 7.75 (d, 2H, benzylidene), 7.43 (d, 2H, 4-aminophenyl), 7.26 (m, 5H, naphthalene), 6.65 (d, 2H, 4-aminophenyl) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.5, 160.3, 152.3, 151.2, 143.5, 136.4, 135.4, 129.9, 128.6, 128.5, 128.4, 127.7, 127.7, 126.5, 126.3, 126.2, 124.4, 116.4, 115.4 ppm; MS (ES+, ToF): *m*/*z* = 393 (\[M + 1\]^+^).

### *N*′-*\[4*-*\[(Propylimino)methyl\]benzylidene\]*-*4*-*aminobenzoic acid hydrazide* (**48**, C~18~H~20~N~4~O) {#d29e19286}

Yield: 63.5 %; TLC: *R* ~f~ = 0.30; IR (KBr): $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \bar{\nu } $$\end{document}$ = 1,696 (C=N str., CH=N), 1,618 (C=O str., secondary amide), 1,511 (C=C skeletal str., phenyl nucleus), 1,464 (CH~3~ asym. bending, R--CH~3~), 1,276 (C--N str., Ar--NH~2~), 827 (C--H out of plane bending, 1,4-disubstituted benzene ring) cm^−1^; ^1^H NMR (MeOH-*d* ~*4*~): *δ* = 7.95 (d, 2H, benzylidene), 7.93 (s, 1H, --CH=N), 7.45 (d, 2H, benzylidene), 7.32 (d, 2H, 4-aminophenyl), 6.85 (d, 2H, 4-aminophenyl), 3.66 (t, 2H, --C~3~H~7~), 0.94 (t, 3H, --C~3~H~7~) ppm; ^13^C NMR (DMSO-*d* ~*6*~): *δ* = 163.7, 160.4, 151.6, 143.5, 136.5, 129.7, 128.5, 124.2, 116.3, 58.5, 24.9, 11.4 ppm; MS (ES+, ToF): *m*/*z* = 309 (\[M + 1\]^+^).

Evaluation of antimicrobial activity: determination of MIC {#Sec13}
----------------------------------------------------------

The antimicrobial activity of the synthesized compounds was evaluated against Gram-positive bacteria *Staphylococcus aureus* MTCC 2901 and *Bacillus subtilis* MTCC 2063, the Gram-negative bacterium *Escherichia coli* MTCC 1652, and fungal strains *Candida albicans* MTCC 227 and *Aspergillus niger* MTCC 8189, using the tube-dilution method \[[@CR19]\]. Dilutions of test and standard compounds were prepared in double-strength nutrient broth I.P. (bacteria) or Sabouraud dextrose broth I.P. (fungi) \[[@CR43]\]. The samples were incubated at 37 °C for 24 h (bacteria), at 25 °C for 7 days (*A. niger*), or at 37 °C for 48 h (*C. albicans*) and the results were recorded in terms of MIC.

Determination of MBC/MFC {#Sec14}
------------------------

The minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) were determined by subculturing 100 mm^3^ of culture from each tube (which remained clear in the MIC determination) on fresh medium. MBC and MFC values are the lowest concentrations of compound that produce a 99.9 % end point reduction \[[@CR44]\].

Antiviral assays {#Sec15}
----------------

The antiviral assays (except anti-human immunodeficiency virus (HIV) assay) were based on inhibition of virus-induced cytopathicity in CRFK (feline corona virus and feline herpes virus), HEL (herpes simplex virus type 1 (HSV-1), HSV-2 (G), vaccinia virus, and vesicular stomatitis virus), Vero (parainfluenza-3, reovirus-1, Sindbis, Coxsackie B4, and Punta Toro virus), and HeLa (vesicular stomatitis virus, Coxsackie virus B4, and respiratory syncytial virus) cell cultures. Confluent cell cultures in microtiter 96-well plates were inoculated with 100 cell culture inhibitory dose-50 (CCID~50~) of the virus (1 CCID~50~, being the virus dose infecting 50 % of the cell cultures) in the presence of different concentrations (100, 20, 4, ... μg/cm^3^) of the test compounds. Viral cytopathicity was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds.

Evaluation of anti-HIV activity {#Sec16}
-------------------------------

The anti-HIV activity and cytotoxicity were evaluated against HIV-1 strain IIIB and HIV-2 strain ROD in MT-4 cell cultures by use of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Briefly, virus stocks were titrated in MT-4 cells and expressed as the 50 % cell culture infective dose (CCID~50~). MT-4 cells were suspended in culture medium at 1 × 10^5^ cells/cm^3^ and infected with HIV at a multiplicity of infection of 0.02. Immediately after viral infection, 100 mm^3^ of the cell suspension was placed in wells of a flat-bottomed microtiter tray containing different concentrations of the test compounds. After incubation for four days at 37 °C, the number of viable cells was determined by use of the MTT method. Compounds were tested in parallel for cytotoxic effects in uninfected MT-4 cells.

Evaluation of anticancer activity {#Sec17}
---------------------------------

The anticancer activity of compounds **1**--**48** was determined against human colon (HCT116) and breast (MCF7) cancer cell lines. All cell lines were cultured in RPMI 1640 (Sigma) supplemented with 10 % heat-inactivated fetal bovine serum (FBS) (PAA Laboratories) and 1 % penicillin/streptomycin (PAA Laboratories). Cultures were maintained in a humidified incubator at 37 °C in an atmosphere of 5 % CO~2~. Anticancer activity of synthesized compounds at different concentrations was assessed by use of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma) assay, as described by Mosmann \[[@CR22]\], but with minor modification, after incubation for 72 h. Assay plates were read by use of a spectrophotometer at 520 nm. Data generated were used to plot a dose--response curve from which concentrations of the test compounds required to kill 50 % of cell population (*IC* ~50~) were determined. Anticancer activity was expressed as the mean *IC* ~50~ from three independent experiments.

QSAR studies {#Sec18}
------------

The structures of **1**--**48** were first pre-optimized by use of MM^+^ procedure included in Hyperchem 6.03 \[[@CR45]\] and the resulting geometries were further refined by means of the semiempirical method PM3 (Parametric Method-3). We chose a gradient norm limit of 0.04 kJ/Å for the geometry optimization. The lowest energy structure was used for each molecule to calculate physicochemical properties using TSAR 3.3 software for Windows \[[@CR46]\]. Further, the regression analysis was performed by use of the SPSS software package \[[@CR47]\].

The antiviral assays were performed by the Laboratory of Virology and Chemotherapy at the Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
